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aa     amino acid 
AdipoR1 / R2    adiponectin receptor 1 / 2 
AdipoRs    adiponectin receptors 
AMPK     adenosine monophosphat activated protein kinase 
APC     allophycocyanin 
APN     adiponectin 
APN-KO    adiponectin-deficient [knock-out] 
APPL-1  adaptor protein containing pleckstrin homology domain, 
phosphotyrosine-binding domain and a leucine zipper motif 1 
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IL     intereukin  
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JNK     c-Jun N terminal kinase 
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MAPK     mitogen activated protein kinase 
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mTOR     mammalian target of rapamycin 
NFκB     nuclear factor kappa-light-chain-enhancer of activated B cells 
NK     natural killer 
PBMC     peripheral blood mononuclear cells 
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PPAR     peroxisome proliferator-activated receptors 
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SEB     Staphylococcal enterotoxin B t 
SEM     standard error of the mean 
SNP     single nucleotide polymorphism 
STAT     signal transducer and activator of transcription  
TIRC7     T cell immune response cDNA 7 
TLR-L     Toll-like receptor ligand 
TLR4     Toll-like receptor 4 
TLR8     Toll-like receptor 8 
TNFα     tumor necrosis factor α 
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SUMMARY 
Adiponectin (APN), an adipokine constitutively produced by fat tissue is present abundantly 
in different oligomeric forms in human plasma and has been shown to exert anti-
inflammatory effects in various disease models. While the influence of APN on monocytes, 
macrophages and epithelial cells has been extensively investigated, little has been known 
about its role in modulating lymphocytes and their function, especially T and natural killer 
(NK) cells so far. This study describes the distribution of adiponectin receptor 1 and 2 
(AdipoR1 and 2) on human and murine T cells, their regulation upon antigen stimulation and 
the effects of APN on T cell responses. Further, it deals with the AdipoRs expression on 
human and murine NK cells and their subsets, and characterizes the APN influence on human 
NK cells as well as on murine NK cells in vitro and in a murine model.  
In this thesis I show that only a minority of human and murine T cells expresses AdipoRs on 
their surface but most T cells store AdipoRs intracellular. Human AdipoRs co-localize with T 
cell immune modulatory molecules CTLA-4 and TIRC7 within clathrin coated vesicles. 
Antigen stimulation results in an upregulation of both receptors on the surface of human and 
murine T cells. The expression is mostly restricted to antigen activated T cells as determined 
by CD137 and tetramer staining and is co-expressed with human CTLA-4. Incubation of APN 
results in a diminished antigen induced T cell expansion. Analysis of the mechanism on the 
generation of antigen activated T cells displays an enhancement of apoptosis and an inhibition 
of proliferation by APN. In accordance, APN deficient [(knockout)-KO] mice exhibit reduced 
frequencies of CD137
+
 T cells upon Coxsackie virus B3 infection. Additionally, APN 
diminishes human T cell cytokine production in response to antigen stimulation.  
The majority of human CD56
dim
 NK cells express surface AdipoRs while most CD56
bright
 NK 
cells lack AdipoRs. In contrast, only a small subset of murine mature NK cells expresses 
surface AdipoRs but the majority stores them intracellular and exposes them on the cell 
surface upon CVB3 infection in a similar manner as human T cells. Cytotoxicity is not 
impaired by APN while Toll-like receptor (TLR) ligand (TLR-L) induced interferon γ (IFNγ) 
secretion is reduced in human NK cells. Uninfected APN-KO mice reveal elevated 
frequencies of NK cells with lower effector NK cells displaying a decreased cytotoxic 







NK cells NKG2D expression required for NKG2D-dependent cytolytic activation is lower in 
uninfected APN-KO mice. Upon CVB3 infection murine NK cell function including 
degranulation and IFNγ production was restored.  
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Taken together these data describes APN as an anti-inflammatory negative T and NK cell 
regulator. In future studies it is therefore of great interest to analyze the prognostic and 
therapeutic potential of APN in inflammatory diseases.  
 
 






Adiponektin (APN), ein vom Fettgewebe kontinuierlich sekretiertes Adipozytokin zirkuliert 
in hohen Konzentrationen im Plasma. Neben seinen vielseitigen metabolischen Funktionen, 
wird APN als ein anti-inflammatorischer Modulator beschrieben. Während der Einfluss von 
APN auf Monozyten, Makrophagen und epitheliale Zellen mehrfach untersucht wurde, 
existieren nur wenige Daten, die die Wirkung von APN auf Lymphozyten beschreiben.  
In dieser Arbeit werden die Adiponektin Rezeptor 1 und 2 (AdipoR1 und 2) Expression auf 
humanen und murinen T Zellen, ihre Regulation während der Antigenaktivierung, sowie die 
Effekte des APNs auf T Zellen beschrieben. Des Weiteren wird die AdipoRs Expression auf 
humanen und murinen NK Zellen und deren Subpopulationen gezeigt und die Wirkung von 
APNs auf die Funktion humaner NK Zellen charakterisiert. Zusätzlich wird in dieser Arbeit 
der Effekt von APN auf murine NK Zellen in einem in vitro Model dargestellt. 
Wir zeigen, dass lediglich ein geringer Prozentsatz an humanen und murinen T Zellen 
AdipoRs auf der Oberfläche exponiert, während beide Rezeptoren von der Mehrheit der T 
Zellen intrazellulär exprimiert wird. Humane AdipoRs ko-lokalisieren in T Zellen gemeinsam 
mit den Immunmodulatoren CTLA-4 und TIRC7 in Clathrin umhüllten Vesikeln. Die 
Stimulation von T Zellen mit Antigenen resultiert in einer Oberflächenexpression beider 
Rezeptoren auf humanen und murinen T Zellen. Die AdipoRs Oberlächenexposition 
beschränkt sich hauptsächlich auf antigenaktivierte T Zellen, welche durch die Expression 
von CD137 und durch Tetramerfärbungen charakterisiert wurden, und mit CTLA-4 ko-
exprimiert werden. APN verringert die antigeninduzierte T Zell Expansion indem die 
Apoptose von CD137
+
 T Zellen verstärkt und deren Proliferation inhibiert. Damit 
einhergehend weisen APN defiziente [(knockout)-KO] Mäuse nach Coxsakie Virus B3 
(CVB3) Infektion erhöhte Frequenzen von CD137
+
 T Zellen auf. Zusätzlich verringert APN 
die antigenstimulierte Zytokinsekretion von humanen T Zellen.  
Im Gegensatz, exprimieren nahezu alle humanen CD56
dim
 NK Zellen beide APN Rezeptoren 
auf ihrer Oberfläche, während den meisten CD56
bright
 NK Zellen die Oberflächenrezeptoren 
fehlen. Demgegenüber exprimiert nur eine kleine Subpopulation muriner, reifer NK Zellen 
beide Rezeptoren auf ihrer Oberfläche. Die meisten murinen NK Zellen speichern die 
AdipoRs intrazellulär und exponieren diese nach CVB3 Infektion an der Oberfläche. APN 
beeinflusst nicht die Zytotoxizität, inhibiert jedoch die Toll-like Rezeptor (TLR) Ligand  
 





(TLR-L) stimulierte IFNγ Sekretion humaner NK Zellen. APN-KO Mäuse weisen erhöhte 
NK Zell Frequenzen auf, wobei ihre zytotoxische Degranulation erniedrigt ist. 






 Effektor NK Zellen, ist 
die NKG2D Expression in APN-KO Mäusen vermindert. Die CVB3 Infektion führt zur 
Wiederherstellung der NK Zell Funktionen, einschließlich der Zytotoxizität und IFNγ 
Produktion.  
Insgesamt beschreiben diese Daten APN als einen anti-inflammatorischen, negativen T und 
NK Zell Regulator. Die Analyse des prognostischen und therapeutischen Potentials von APN 
im Zusammenhang mit entzündlichen Erkrankungen könnte somit von zentraler Bedeutung 

























  Introduction 
 




1.1.1 Gene and expression  
Adiponectin (APN) was discovered simultaneously by for groups in the mid-1990s. Scherer et 
al. as well as Hu et al. isolated adiponectin cDNA from murine adipocyte cell lines and 
named it Acrp30 (adipocyte complement-related protein of 30kDa) and AdipoQ respectively 
[1, 2]. Further it was found as the most abundant transcript in human adipose tissue (apM1, 
adipose most abundant gene transcript 1) [3] and purified from human plasma as a gelatin-
binding protein, GBP28 [4].  
 
 
Figure 1:  Location and genomic structure of ADIPOQ. Human ADIPOQ is located on chromosome 3q27 
consisting of three exons (E1-E3) and two introns (I1-I2). The human ADIPOQ spans 17kb. Within 
the 4.6kb mRNA 735bp are coding for the 244aa protein. Modified [5]. 
 
The human adiponectin gene, ADIPOQ is located on chromosome 3q27 encoding for a 244-aa 
polypeptide and sharing 84% protein sequence identity with mouse APN (encoded on Chr.16 
16.16.0cM). The coding sequence of 735bp is transcribed [5] from a 17kb spanning genomic 
region containing three exons and two introns (Fig.1) [6]. The translation starts at exon 2 and 
ends at exon 3 so that exon 1 and parts of exon 3 are left untranslated [6]. The special locus is 
associated with the susceptibility to type 2 diabetes and cardiovascular disease, two diseases 
highly related with the protective role of APN [7]. Within 16 identified polymorphisms of 
ADIPOQ [8] many are associated with clinical conditions.  
APN is mainly synthesized by adipocytes and therefore ranks among the fat derived 
hormones named adipokines. Several studies also reported expression in skeletal muscle [9], 
liver [10] and cardiac tissue [11]. Plasma APN levels determined by various genetic, 
hormonal, inflammatory, dietary and pharmacological factors, range from 2 to 30µg/ml, thus  
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accounting for 0.01% of total plasma proteins in humans [12]. Plasma values are decreased in 
obese [13] and diabetes type 2 [14] patients as well as in individuals with cardiovascular 
diseases [15]. Values increase with weight loss thereby enhancing sensitivity to insulin [16]. 
Studies for circulating APN levels reported that five single nucleotide polymorphisms (SNPs) 
were genome-wide significant as determinants for APN plasma values, whereas SNPs in the 
ADIPOQ locus demonstrated the strongest association [17]. Surprisingly APN values 
inversely correlate with cardiovascular diseases [14], obesity-linked diseases like insulin 
resistance, the development of type 2 diabetes and obesity itself. The expression of APN 
decreases with obesity, considered as a chronic inflammation, and insulin resistance, 
determined by pro-inflammatory cytokines (TNFα, IL-6, IL-18) suppressing APN 
transcription [18]. Further studies have shown a relationship between APN levels and gender 
with higher values in women than men although women have a higher body fat content. This 
paradoxical relationship might be due to the involvement of sex steroids as shown by 
Nishizawa et al. [19]. Finally, human and mice in vitro and in vivo studies revealed that APN 
expression and secretion is regulated at both transcriptional and posttranscriptional levels. 
One of the key players is the nuclear receptor peroxisome proliferator activated receptor γ 
(PPARγ) which acts as a transcription factor. Its activation leads to increased APN expression 
and secretion, due to the binding of PPARγ to a putative PPARγ responsive element (PPRE) 
on the APN promotor [20]. PPARγ is activated by its natural ligands such as free fatty acids 
and eicosanoids and by its agonists such as thiazolidinediones (TZDs). These anti-diabetic 
drugs are used in the treatment of type 2 diabetes which results in enhanced insulin sensitivity 
[18, 19]. Posttranscriptional regulation of APN including hydroxylation, glycosylation and 
disulfide bound formation is determined among others by PPARγ induced genes coding for 
chaperons involved in the multimerization of APN [18, 20].  
 
1.1.2 Protein and receptors 
Structurally APN contains four differentiable domains: an amino-terminal signal sequence, 
followed by a species specific variable region, a collagenous domain and a carboxy-terminal 
globular domain that binds to the adiponectin receptor (AdipoR) [21]. The 30kDa monomeric 
form has not yet been detected in the circulation and is thought to appear only in the 
adipocyte. Synthesized as single subunits the full-length monomers trimerize through their 
globular domains and form low molecular weight (LMW) complexes, which themselves  
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associate through the collagenous domains via disulfide bonds to hexamers (middle molecular 
weight structures, MMW) and higher molecular weight (HMW) structures (Fig. 2). There 
exists a fourth configuration of APN, the globular one (gAPN), which results of a cleavage of 




Figure 2:  Domains and configurations of APN. APN contains four domains which form different structures 
of the protein at which the LMW and HMW are the most abundant in plasma [19, 25] 
 
In plasma the protein is mainly found as a hexamer and HMW isoform. [8, 12]. It has been 
suggested that the various isoforms have different target tissues and/or different biological 
effects [5]. Whereas the HMW isoform is considered to be responsible for its pro-
inflammatory actions, the LMW isoform exerts the anti-inflammatory effects [22], but this 
requires the measuring of APN isoforms when studying its action and function. On the other 
hand circulating APN is composed of all oligomers hence it might be the ratio between them, 
rather than their respective concentrations, which determines the physiological activity of 
APN [23]. Further posttranslational modifications of the adipokine like hydroxylation and 
glycosylation determine its activity and receptor binding [5].  
APN exerts its function mainly through binding with its globular domain to two receptors, 
Adiponectin receptor 1 and 2 (AdipoR1/AdipoR2). Both receptors are structurally related and 
are with 95% identity highly conserved in humans and mice [21]. Protein sequence alignment 
shows that the internal N-terminal 69 aa of AdipoR1 and the 79 aa of AdipoR2 are specific 
for each receptor whereas the rest of these proteins is highly homologous with 80% identity. It 
is therefore not surprising that although both receptors have similar effects they also have 
individual signaling preferences (elaborated in section 1.1.4) [24] AdipoR1 and 2 are 
expressed at detectable levels in most tissues like skeletal muscle, endothel, brain and in the 
heart. Studies also report expression of both receptors in cells of the immune system like  
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monocytes, macrophages, B and NK cells but only a small percentage of T cells [25]. 
Whereas AdipoR1 is the major receptor in skeletal muscle and heart, AdipoR2 is most 
abundant in the liver [16]. Studies demonstrated that both receptors bind globular APN and 
full-length APN but with different affinities. AdipoR1 serves as a high-affinity receptor for 
globular APN and a low-affinity receptor for full-length APN. In contrast AdipoR2 is an 
intermediate affinity receptor for both isoforms. Each receptor consists of seven 
transmembrane domains, but they are structurally, topologically and functionally distinct from 
all other reported G-protein coupled receptors with an internal N-terminus and external C-
terminus [21]. Hug et al. [26] identified a third receptor being capable of binding APN, T-
cadherin. As a cell-surface receptor T-cadherin lacks an intracellular domain which is 
required for signal transduction. Consequently T-cadherin is only able to serve as a co-
receptor by competing with AdipoR1 and AdipoR2 for APN binding or is believed to 
interfere with APN signal transduction [12, 27]. Effects of APN are also regulated by 
AdipoRs distribution and expression levels, which in turn are defined genetically, through 
mediators and by physiological state, like obesity and insulin resistance [16]. Insulin and 
obesity negatively regulates the levels of AdipoRs mRNA [28, 29]. PPARγ and α are also 
able to modulate AdipoRs [30].  
1.1.3 Role of Adiponectin  
Adiponectin has pleiotropic biological effects in different organs and tissues (Fig. 3). It is 
characterized as insulin-sensitizing, antiatherogenic, cardioprotective, tumor growth limiting, 
anit-angiogenic and immunomodulatory /anti-inflammatory adipokine whereas its main 
metabolic functions span the regulation of glucose and lipid metabolism. It increases fatty 
acid oxidation in skeletal muscle and liver and the translocation of the glucose transporter 4 
(GLUT 4) in skeletal muscle [12, 31], which is important for the cellular glucose uptake. APN 
suppresses hepatic glucose output and reduces the synthesis of glucose in the liver leading to 
an improved insulin-signaling and –sensitivity [12]. The absence of the APN gene in APN 
deficient [knock out (KO)] mice has no appreciable effect when placed on a normal diet, but 
on a high fat/sucrose diet they develop severe insulin resistance [16]. In accordance 
administration of APN protects mice with diet induced obesity against insulin resistance [32], 
the major ingredient of type 2 diabetes. Tow SNPs related pathophysiological conditions are 
low APN plasma concentrations [6], high risk of type 2 diabetes [9], obesity and insulin 
resistance [10] and cancer [11]. Studies revealed that low initial plasma concentrations of  
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Figure 3: Pleiotropic role of APN. APN is involved in metabolic functions, plays a role in the cardiovascular 
system and negatively regulates the immune system. ↓ indicates inhibition, ↑ indicates activation. 
TNFα, tumor necrosis factor α; NFκB, nuclear factor kappa-light-chain-enhancer of activated B 
cells; VCAM, vascular cell adhesion molecule 1 
 
APN are strongly correlated with the development of type 2 diabetes [14, 33] and high levels 
of APN are associated with a reduced risk of type 2 diabetes [34]. Several studies have shown 
that expression levels of APN are diminished in obesity. The resulting decreased effect of 
APN possibly plays a causal role in the development of insulin resistance. The following 
hyperinsulinemia or an existing obesity leads to a decreased expression of both receptors 
which in turn results in a reduced sensitivity to APN and insulin resistance , a so called 
“vicious cycle”[16]. This suggestion is confirmed by studies which show diminished levels of 
APN and AdipoRs in obesity, insulin resistance and diabetes [28, 31]. Consequently, APN 
protects against insulin resistance and type 2 diabetes through its abilities to improve the 
systemic carbohydrate and lipid profiles [35].  
The activation of endothelial cells and macrophages display an essential component in the 
development of atherosclerosis. APN was shown to decrease endothelial TNFα induced 
adhesion molecule expression thereby inhibiting the adhesion of macrophages [36]. 
Furthermore, APN reduces the ability of macrophages to transform into foamy cells [37] and 
suppresses the TNFα induced endothel activation through inhibition of NFκB [29]. In vivo 
experiments demonstrated that adenoviral mediated APN overexpression reduces the 
formation of atherosclerotic lesions in apolipoprotein E knockout (ApoE-KO) mice, a mouse 
model of atherosclerosis, via the inhibition of TNFα and vascular cell adhesion molecule -1  
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(VCAM-1) expression [38]. In agreement, APN overexpressing ApoE-KO mice are protected 
from developing atherosclerosis compared to wild type (WT) mice [39].  
Low APN levels are associated with cardiovascular diseases. Hypoadiponectinemia is 
associated with coronary artery disease, acute coronary syndrome and hypertension. It 
directly affects signaling in cardiac myocytes and has advantageous effects on several 
pathological heart conditions, including cardiac hypertrophy and myocardial infarction [40]. 
Compared to WT mice APN-KO mice develop larger infarcts which are associated with 
increased myocardial apoptosis and TNFα expression. Adenoviral delivery of APN 
diminished infarct size, apoptosis and TNFα production [41]. Further pressure overload in 
APN-KO mice resulted in enhanced concentric cardiac hypertrophy, which was attenuated by 
adenoviral administration of APN in both APN-KO and WT mice [42]. The beneficial effects 
of APN are referred to an inhibited inflammatory response, decreased myocyte death and 
hypertrophic response [40]. APN plasma values also inversely correlate with classical 
cardiovascular risk factors such as body mass index (BMI), high blood pressure and C-
reactive protein (CRP) levels [43].  
Adiponectin has been found to exert anti-angiogenic effects, through the inhibition of 
endothelial cell proliferation and migration [44, 45]. However, many reports describe APN as 
a stimulator of angiogenesis in APN-KO mice [46] and in a model of overexpression [47].  
A number of studies indicated an inverse relationship between APN levels in vivo and the risk 
of malignancies. Low levels of plasma APN were found in endometrial cancer, 
postmenopausal breast cancer, colon cancer, renal cancer, gastric cancer, prostate cancer 
leukemia and other hematological malignancies. Two mechanisms are thought to exert APN’s 
anti neoplastic effects on tumor cells. First, APN can act directly via receptor mediated 
signaling pathways on cancer cells expressing AdipoRs and secondly, it may modulate insulin 
sensitivity at the target tissue resulting in an impaired inflammatory response and 
angiogenesis [12]. In vitro studies, dependent on the used APN isoform, indicated that 
involved receptor mediated signaling pathways lead to the induction of apoptosis [48-50], and 
the inhibition of migration [51, 52] and proliferation [53, 54] in cancer cells. Indirectly, 
among others, Adiponectin has an anti-proliferative effect via selectively binding to several 
mitogenic growth factors [45]. This interaction constricts the involved growth factors from 
their binding to the membrane receptors and prevents the induction of proliferation of tumor 
cells.  
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Finally APN has been found to be an important regulator of the immune response affecting 
carcinogenesis by inhibiting the growth and inducing apoptosis of myelomonocytic progenitor 
cells [55].  
 
1.1.4 Signaling pathways 
Adiponectin stimulates several intracellular signaling pathways when binding to its receptors 
including peroxisome proliferator activated receptors (PPARs), nuclear factor -κB (NFκB), 
mammalian target of rapamycin (mTOR), MAPK (mitogen activated protein kinase) 
cascade, signal transducer and activator of transcription (STAT3) and adenosine 
monophosphat (AMP) activated protein kinase (AMPK) [12] (Fig. 4). Recent studies 
identified among others [24] the adaptor protein containing pleckstrin homology domain, 
phosphotyrosine-binding domain and a leucine zipper motif (APPL-1) interacting N-terminal 
and intracellular with AdipoRs thereby participating in APN signaling by mediating and 
enhancing its effects [56, 57]. Overexpression of APPL-1 enhances the effects of APN 
whereas the suppression by small interfering RNA (siRNA) abrogates APN function 
including the phosphorylation of AMPK and the associated glucose uptake and fatty-acid 
oxidation [56]. APPL-1 further functions as mediator of other signaling pathways through 
intracellular binding to receptors and proteins. These signaling pathways mainly impair cell 
proliferation, survival and apoptosis, endosomal trafficking and chromatin remodeling [58, 
59].  
AMPK plays a central role in APN signaling. It is a master regulator of cellular energy 
homeostasis responding to low intracellular levels of ATP. As an energy sensor it positively 
regulates signaling pathways that replenish ATP supplies like transcription and translocation 
of glucose transporter 4 (GLUT4) resulting in increased glucose uptake and fatty-acid 
oxidation. On the other hand it negatively regulates several proteins central to ATP 
consuming processes leading to a downregulation and/or inhibition of gluconeogenesis, lipid 
and protein synthesis. Metabolic functions and the insulin sensitizing effects of APN are 
among others (see PPRAα) mainly exerted through the phosphorylation of AMPK via APPL-
1 promoting glucose utilization. This results in increased fatty-acid oxidation, increased 
glucose uptake and reduced gluconeogenesis. Through AMPK, APN is involved in the 
regulation of AMPK downstream targets, like mTOR and p53. Whereas the activated,  
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phosphorylated AMPK inhibits mTOR resulting in the suppression of cell proliferation, 
stimulation of p53 results in cell cycle arrest and the induction of apoptosis [56].  
The peroxisome proliferator-activated receptors (PPARs) are nuclear, ligand dependent, 
transcription factors involved in lipid metabolism, glucose homeostasis, cellular 
differentiation, apoptosis and inflammation control. They are activated endogenously by fatty-
acid derivatives and eicosanoids, additionally by leukotrienes (PPARα) and prostaglandins 
(PPARγ).  
 
Figure 4: Involvement of APN in intracellular signaling pathways. APN exerts its functions by modulating 
several signaling pathways and their mediators. Depicted are important through APN impaired cell 
signals and factors regulating APN. If JNK, ERK 1/2 and Jak/Stat3 are activated or inhibited via 
APPL-1 remains to be investigated. - indicates inhibition, + indicates activation. TNFα, tumor 
necrosis factor α; IL-6, interleukin 6; TZD, thiazolidinediones; PPARα (γ), peroxisome proliferator 
activated receptor α (γ); APPL-1, adaptor protein containing pleckstrin homology domain, 
phosphotyrosine-binding domain and a leucine zipper motif; AMPK, adenosine monophosphat 
activated protein kinase; JNK, c-Jun-N-terminal kinase; ERK 1/2, extracellular signal-related 
kinases 1and 2; Jak/Stat3, Janus kinase/signal transducer and activator of transcription;  mTOR, 
mammalian target of rapamycin; IκB, inhibitor of kappa-light-chain-enhancer of activated B cells; 
NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; p38,mitogen activated protein 
kinase p38; p53, tumor protein 53 
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Whereas PPARα is highly expressed in liver, skeletal muscle, kidney, heart and the vascular 
wall, PPARγ is predominantly detected in adipose tissue, intestine and macrophages [60]. 
Studies revealed that APN metabolic functions can be further explained by the APN 
activation of PPARα resulting in enhanced fatty-acid combustion, energy consumption and 
improved insulin sensitivity in vivo [12, 32]. Interestingly, studies indicated that AMPK is 
mainly activated by AdipoR1 whereas stimulation of PPARα could be attributed to binding to 
AdipoR2 [61]. However, it remains an active field of research which isoforms of APN 
primarily triggers the activation of AMPK [12]. 
APN exhibits tumor growth limiting effects by interfering with Jak (Janus kinase)/STAT3 and 
several MAPK cascades. Cytokines like IFNα and γ, as well as IL-6 signals through the 
Jak/STAT pathway and ensure a rapid signal translation. The cytokine induced 
phosphorylation of receptor associated Jaks is followed by the phosphorylation of STATs, 
which dimerize, translocate to the nucleus and activate the transcription of cytokine inducible 
genes involved in regulation of cell survival and differentiation. APN decreases STAT3 
phosphorylation and reduces cell growth and migration. Moreover, it was found to suppress 
constitutively active STAT3 signaling [62]. MAPK cascades are composed of MAPKKK 
(MAP-kinase-kinase-kinase), a MAPKK (MAP-kinase-kinase) and MAPK connected in 
series. MAPK are divided into three groups following three signaling pathways the stress 
activated kinase c-Jun-N-terminal kinase (JNK), the stress and tumor necrosis factor activated 
kinase p38 and the mitogen activated, extracellular signal-related kinases 1and 2 (ERK). 
Studies demonstrated an involvement of APN in all three signal transductions. APN increased 
JNK activity resulting in apoptosis [62, 63] and p38 activity, which is associated with 
metabolic effects of APN [57]. In contrast Erk1/2 signaling is inhibited by APN leading to 
cell cycle arrest and apoptosis [50, 64]  
The anti-inflammatory effects of APN could be explained by activation of PPARs which 
inhibit the expression of pro-inflammatory genes in various cell types, like cytokines and C 
reactive protein (CRP) [60, 65]. Further, anti-inflammatory effects are partially based on the 
APPL-1 dependent AMPK mediated activation of phosphatidylinositol 3-kinase (PI3K) 
pathway and the suppression of NFκB pathway through suppression of inhibitor NFκB 
phosphorylation [29, 66] which results in decreased expression of pro-inflammatory NFκB 
target genes like a variety of chemokine receptors and ligands, IL-6, CRP and IFNγ. A variety 
of mediators of the above mentioned pathways are cross linked among each other and to  
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further cell signals. Consequently, APN is indirectly involved in a number of signal 
translations.  
 
1.2 Immunomodulatory effects of Adiponectin 
Among its metabolic, antiatherogenic, cardioprotective and anti-oncogenic properties several 
studies indicate APN to be involved in the regulation of the immune system. The majority of 
these findings refer to the effects of APN on cells of the innate immune system and 
inflammation, only little is known about the influence of APN on the adaptive immune 
system and/or response.  
APN was shown to influence the function of myelomonocytic cells by reducing the 
phagocytic activity of human macrophages, inhibiting the proliferation of myelomonocytic 
cells and the production of tumor necrosis factor (TNF) in response to stimulation with 
lipopolysaccharide (LPS) [55]. It impairs the leukocyte adhesion by inhibiting the adhesion 
molecule expression on the endothel [36]. APN also reduces secretion of pro-inflammatory 
cytokines TNFα [55], IL-6 [67] and IFNγ by LPS activated human macrophages and induces 
the production of anti-inflammatory cytokines IL-10 and IL-1 receptor antagonist (IL-1RA) in 
dendritic cells (DCs), monocytes and macrophages [68]. Further APN negatively regulates the 
response of macrophages to Toll-like receptor (TLR) stimulation through suppression of TLR 
induced NFκB activation [69]. Moreover, APN in vitro and in vivo promotes the macrophage 
polarization towards the anti-inflammatory M2 phenotype and supports the resolution of 
inflammation [70]. Recently APN was also identified as a negative regulator of NK cell 
cytotoxicity [71].  
Other data illustrate pro-inflammatory effects of APN depending on isoform and 
environment. gAPN and the HMW isoform was shown to induce the inflammation mediators 
TNFα and IL-6 in monocytes, macrophages and the endothel through the activation of NFκB 
[72, 73]. Saijo et al. described APN dependent enhancement of IL-8 secretion in the presence 
of LPS whereas in the absence of LPS the IL-8 secretion was suppressed. Further LPS 
presence results in an increased phagocytosis of apoptotic cells by macrophages when 
culturing with APN [74].  
Concerning the effects of APN on mediators of the adaptive immune system little is known. 
Several published effects of APN on the adaptive immune system are indirect. Wolf et al.  
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revealed that APN incubation of macrophages leads to a reduced ability to evoke an allogenic 
T cell response [68]. Further APN modulates the DC activity which results in a decreased T 






 regulatory T cells [75] 
and reduces T cell recruitment in atherogenesis through downregulating T cell 
chemoattractants in macrophages [76]. Finally, APN was shown to act in vivo and in vitro not 
only as a hematopoietic stem cell factor stimulating proliferation while retaining the cells in a 
functionally immature state [77] but also as a stimulating factor of adult hippocampal neural 
stem cells [78]. Contrary, APN was also revealed as a negative regulator of hematopoiesis 
inhibiting directly proliferation of myelomonocytic progenitors [55] or indirectly through 
inducing changes in stromal cells and hence suppressing B cell lymphopoesis [79] . Through 
its immunomodulatory effects APN has a considerable influence on carcinogenesis.  
 
1.2.1 Anti-inflammatory activities of Adiponectin in in vivo models 
APN has been shown to possess profound immunoinhibitory and anti-inflammatory effects in 
various disease models. In accordance APN-KO mice are more susceptible to inflammatory 
diseases.  
In APN-KO mice APN administration had beneficial effects and alleviated disease severity by 
suppressing the TNF expression in the liver in alcoholic and non-alcoholic fatty liver disease 
[80] as well as in carbon tetrachloride induced liver fibrosis where APN attenuates the 
induced fibrosis [81]. In addition, APN protects from endotoxin induced liver injury in 
another model of fatty liver, the KK-A
y
 obese mouse model through modulation of TNFα 
[82]. Moreover APN-KO mice are more prone to inflammatory diseases like colitis [83] and 
sepsis [84]. Compared to WT, APN-KO mice displayed higher mortality and significant 
increased inflammatory cytokine levels [84]. Adenoviral supplementation of APN has been 
shown to have protective effects due to the inhibition of chemokine production in intestinal 
endothelial cells, infiltration of macrophages and the synthesis of pro-inflammatory cytokines 
[83]. APN was also found to exert anti-inflammatory effects in viral myocarditis mouse 
models. Leptin-deficient ob/ob (OB) mice showed impaired expression of cardiac adiponectin 
that may contribute to the progression of viral myocarditis through enhanced expression of 
TNFα. [85]. Consistently, APN replacement and induction of cardiac APN expression 
attenuates myocardial damage provoked by viral myocarditis and survival [86, 87]. Finally, 
cardiac allografts transplanted into APN-KO mice showed severe acute rejection relative to  
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lymphocytes, significantly higher levels of TNFα and IFNγ [88]. Interestingly, the disruption 
of AdipoRs results in systemic inflammation [61].  
 
1.3 T Cells 
T cells are highly specialized lymphocytes belonging to the adaptive immune system and 
account for 70% of the lymphocytes in human blood. They originate from the bone marrow, 
develop in the thymus and are responsible for the regulation of immune responses, specific 
elimination of pathogens and play a central role in cell-mediated immunity. T cells can be 
distinguished from other lymphocytes like B and natural killer (NK) cells by bearing a T cell 
receptor (TCR) which enables the specific recognition of pathogens, infected and transformed 
cells. To realize these functions precisely T cells pass various steps of selection preventing 
them to recognize “self-antigens” via TCR during their development in the thymus and later 
in peripheral lymphoid organs.  
The TCR is a transmembrane, heterodimeric receptor with a cytosolic C terminus and a 
extracellular N terminus. The exposed part is classified into a constant and variable region 
aligned and stabilized by disulfide bonds. The variable domains determine the specificity of a 
given TCR which is the result of somatic gene rearrangements and alternative splice 
processes. The TCR is associated with the CD3 protein complex The CD3 molecule is 
responsible for the signal transduction of the TCR and its translocation to the T cell surface. 
Other co-receptors associated with the TCR are CD4 and CD8 molecules. The expression of 
either CD4 or CD8 divides T cells into the major classes: CD4
+
 T helper cells and CD8
+
 
cytotoxic T cells. These co-receptors mediate the interaction of the TCR with the constant 
region of MHC class I or II molecules during the antigen recognition of T cells [89, 90]  
 
1.3.1 Regulation of T cells 
T cells are activated in peripheral lymphoid organs by APCs presenting processed antigens 
via MHC molecules. In addition to the interaction between MHC molecules and TCRs 
associated with CD4 or CD8, T cells require further signals to be activated and to proliferate 
and differentiate into effector cells (Fig. 5). The co-stimulatory signal needed is the binding of 
constitutive expressed CD28 molecule/receptor on the T cell surface with B7 proteins (CD80  
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and CD86) on APCs. B7 protein expression on APCs is induced and upregulated during an 
innate immune response. With assistance of CD3 involved in the signal transduction the T 
cell starts to produce IL-2 and to express the IL-2 receptor and enhances auto- and paracrine 
the differentiation and proliferation signals [90]. Activation of human and mice T cells is 
characterized among others through their surface expression of CD137 interacting with 4-
1BBL on activated APCs and can be detected by mAb against CD137 [91]. Cross-linking of 
CD137 is required for T cell expansion and survival, as well as for cytokine production [92, 
93].  
 
Fig. 5: Interaction of TCR/CD3 complex with MHC molecule on APC. The α and β chains of the (TCR) 
bind to antigen (Ag) loaded MHC complex on an APC. Additionally CD4 or CD8 interacts with the 
MHC. Both actions stimulate the T cell (1st signal) through the accessory CD3 chains. However, 
without a 2nd (co-activation) signal, the T cell is anergic or tolerant. The TCR have constant (C) α and 
β (or γ and δ) chains and variable (V) regions. (1) = 1st signal; (2) = 2nd signal. (modified 
merckmanuals.com) 
 
In the course of activation T cells expose an inhibitory receptor being similar to CD28 and 
binding B7 proteins; cytotoxic T lymphocyte antigen 4 (CTLA-4). CTLA-4 has a 
comparatively higher binding affinity to B7 proteins and ensures through a negative feedback 
loop the downregulation of a continuous immune response. Another inhibitory protein 
induced after T cell activation is T cell immune response cDNA 7 (TIRC7) which inhibits 
further T cell proliferation and cytokine response [94, 95]. Regulatory proteins accumulate 
predominantly in cytoplasmatic compartments and are transported after activation to the cell 
surface via cellular traffic systems. CTLA-4 and TIRC7 were shown to co-localize and are 
stored in clathrin-coated vesicles [94] built in order to transport molecules within and between 
the cells. Additional to TCR and co-stimulatory signals provided during the activation T cells  
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upregulate and activate adhesion molecules like Lymphocyte-function-associated protein 1 
(LFA-1) to increase the adhesion to the APC. LFA-1 ligation to intracellular adhesion 




 cytotoxic T cells protect the body by killing cells which are transformed and infected 
with intracellular pathogens. These cells recognize their targets by binding to MHC class I 
molecules loaded with peptide antigens. MHC class I molecules are expressed on every 
nucleated cell of the body. After activation CD8
+
 T cells release their cytotoxic granules 
including perforin and granzyme B. Perforin forms pores in the target cell membrane and 
allows granzyme B to enter, activate the caspase cascade and induce apoptosis. During this 
exocytose process CD107a is transiently located on the T cell surface and can be used as a 
marker for degranulation. Another way to induce apoptosis in target cells is via Fas-ligand 
(FasL) expressed on activated CD8
+
 T cells. FasLs bind to the transmembrane Fas receptor on 
target cells and induces apoptosis in a caspase 8 dependent way. Activated cytotoxic T cells 
are also able to secrete IFNγ and provoke a non-lytic antiviral immune response through e.g. 
induction of MHC molecules. Most effector function of CD8
+
 T cells depend on the presence 
of IL-2 and IFNγ released by CD4+ T cells or IL-1, TNFα or IFNα provided by activated cells 
of the innate immune system [90].  
CD4
+
 helper cells activate and direct other immune cells. They are essential in antibody 
production by B cells, activate and help CD8
+
 cytotoxic T cells and maximize the effector 
function of macrophages. Activation of CD4
+
 cells by loaded MHC class II molecules and co-
stimulatory signals induce the release of cytokines and the differentiation into subclass of 
CD4
+
 T cells, among them TH1 or TH2 cells. TH1 cells produce IFNγ, IL-2 and TNFα and 
promote macrophages to kill phagocytosed pathogens. Furthermore, TH1 cells stimulate the 
lytic activity of CD8
+
 T cells. TH2 cells secrete IL-4, IL-5 IL-6, IL-10 and IL-13 and stimulate 
the differentiation of B cells into plasma cells as well as the production of antibodies. The 
differentiation of CD4
+
 cells into TH1 or TH2 cells promote the immune system into a cell 
mediated or humoral immune response and is driven by the released cytokines of APCs. IL-
12 induces the development of TH1 and suppresses TH2 growth whereas IL-4 is required for 
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1.3.2 Adiponectin and T cells 
To date little is known about the direct modulatory effects of APN on T cells and their 
function. All described effects of APN on T cells are determined and caused by cells of the 
innate immune system. The APN incubation of macrophages resulted in reduced T cell 
recruitment and decreased allogenic T cell response [76] whereas the modulation of DC 
activity led to a decreased T cell proliferation and higher frequencies of T regulatory cells 
[75]. Further studies reported the expression of AdipoRs on the surface of a small 
subpopulation of T cells [25, 96] 
 
1.4 Natural Killer Cells  
Natural killer cells (NK cells) are key players and the first line of defense of the innate 
immune system and are considered to be involved in the regulation of the immune response. 
Proliferation, NK cell-mediated cytotoxicity against tumor and virus infected cells and 
IFNgamma (IFNγ) production display the important defense mechanisms of NK cells which 
are regulated by a wide range of receptors, cytokines and hormones. 
Originally NK cells were identified as large granular lymphocytes having the ability to lyse 
tumor cells without prior sensitization. Later these cells were recognized as a separate 
lymphocyte lineage developing in the bone marrow through discrete stages of maturation [97, 
98] and are present throughout lymphoid and non-lymphoid tissues. Consistent with data in 
the mouse the human NK cell turnover in blood is around two weeks [99, 100]. Human NK 
cells comprise 2-18% of total lymphocytes in peripheral blood and spleen whereas murine 
NK cells represent around 2% of splenocytes [101].  
The mechanism by which NK cells recognize and discriminate target cells from healthy cells 
depends on a dynamic equilibrium of inhibitory and activation receptor signaling through 
corresponding NK cell receptors. Inhibitory NK cell receptors detect the presence of self-
molecules, MHC class I molecules on potential target cells through MHC class I-specific 
receptors. The absence of MHC class I molecules on target cells, downregulated by viruses, in 
transformed cells and upon stress, results in a loss of the inhibitory signal in the NK cell and 
leads to NK cell mediated cytotoxicity [102] via induction of apoptosis. Inhibitory MHC class 
I specific NK cell receptors include most killer cell immunoglobulin-like receptors (KIRs) in  
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humans, lectin-like dimers of the Ly49 family in mice, CD94-NKG2A heterodimers in both 
species and receptors recognizing non-MHC self-molecules [103, 104]  
Activating receptors on NK cells, like NKG2D, NKp46, CD94-NKG2C/E, low affinity Fc 
receptor CD16 (only in human) through which NK cells exert antibody-dependent cell 
cytotoxicity (ADCC), and natural cytotoxicity receptors (NCR) recognize ligands on target 
cells expressed upon stress or bind infectious non-self-ligands, like Toll-like receptors. TLR 
are receptors belonging to the pattern recognition receptors (PRR) of the innate immune 
system and recognize structures which are broadly shared by pathogens. Bearing several Toll-
like receptors (TLR), in vitro exposure of NK cells to TLR ligands (TLR-L) such as 
lipopolysaccharide (LPS) results in enhanced IFNγ production as well as in increased 
cytotoxicity [104] 
Distinct NK cell subsets have been defined and characterized in human as well as in mice 
based on phenotypic, functional and anatomic features (Fig. 6).  
Human NK cells are identified by the absence of the surface molecule CD3 and the 





subsets differing in their function and phenotypic properties. 90% of peripheral NK cell are 
CD56
dim
 and express high levels of KIRs and CD16. CD56
dim
 NK cells display enhanced 





NK cells are CD16
-
, have high levels of CD94-NKG2C/E receptors 
and produce large amounts of cytokines such as IFNγ in response to stimulation with 
interleukin (IL)-12, IL-15, IL-18 [105] and TLR-L [106]  
Besides the fact that all NK cells express the heterodimeric IL-2 receptor (IL-2Rβγ) with 
intermediate affinity for IL-2, this subset appears to express the heterotrimeric high affinity 
IL-2Rαβγ and is therefore able to proliferate in response to low dose of IL-2. Both subsets 
express constitutively receptors for monocyte-derived cytokines such as IL-1, IL-10, IL-12, 
IL-15 and IL-18. Thus their function and activation can be mediated by monocytes [105]. 
Several groups proposed that CD56
bright
 cells are precursors of the CD56dim NK subset 
displaying longer telomere length and the ability to differentiate in contact with fibroblasts 
into CD56
dim
 NK cells [78, 79]. 
Mouse NK cells mainly characterized by the expression of NKp46 and DX5 and the absence 
of CD3 can be subdivided into four subsets, based on their developmental expression of 




 state and leads the  
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Fig.6: Comparison of mouse and human NK cells. (A) CD27
hi
 NK cells produce larger amount of cytokines 
upon monokine (e.g. IL-12/IL-18) stimulation and show higher migration capacity than CD27low 
(CD27
lo
) NK cells. The major proportion of the CD27
low
 subset expresses inhibitory Ly49 receptors and 





cells produce high levels of cytokines in response to monokines compared with CD56
dim
 NK cells. The 
human CD56
dim
 subset has a high expression of KIRs and exhibits higher cytotoxic activity than the 
human CD56
bright
 subset. Adapted from [107].  
 












 stages, each 
of them having distinct phenotypic features and gene profiling. The CD11b
low
 subset is mostly 
found in bone marrow, lymph nodes and liver whereas CD11b
high
 NK cells display the 
majority in spleen, peripheral blood and lung. Transcriptome analysis revealed the largest 
differences between these two subsets. Further the CD11b
low














, are closely related to each other but differ in their proliferative potential 
with CD27
low
 having the highest potential to proliferate and giving rise to all other subsets. 
Hence, the DN NK cells are suggested to be the immature NK cells with low levels of Ly49 
receptor and DX5. The CD11b
high
 subset, with high levels of Ly49 receptor, can also be 











positive (DP)] subset displaying the most potent effector cells. Both subsets show comparable  
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cytotoxic capacity against class I MHC mismatched NK cell sensitive (NKG2D ligand 
expressing) target cells, however, only the DP NK cells are able to kill MHC class I and 
NKG2D ligand expressing cells. Thereby, the DP NK cell subset displays a non-NKG2D-















 subset is shown to be most susceptible to spontaneous apoptosis and 
appears to show the end stage of NK cells before cell death. [107, 108].  
 
1.4.1 Adiponectin and Natural Killer cells 
In various studies APN was shown to display anti-inflammatory activity. Concerning its role 
in NK cell function and activity there exist few and conflicting data whereas the expression of 
AdipoRs on NK cells was approved [25, 96].  
Kim et al. [71] described APN as a negative regulator of IL-2 induced cytotoxicity in murine 
NK cells. APN was found to suppress IL-2 enhanced but not basal cytotoxicity by induction 
of AMPK resulting in an AMPK mediated inhibition of NFκB activation. IFNγ, one of NFκB 
target genes, also enhances NK cell cytotoxicity and can be induced by IL-2. In this study 
APN was shown to down regulate IFNγ production leading to an inhibition of FasL (Fas 
ligand) and TRAIL (tumor necrosis factor related apoptosis inducing ligand) expression. FasL 
and TRAIL are important ligands for the induction of apoptosis when binding to FasR and 
death cell receptors on target cells.  
On the other hand APN was described as inducer of cytotoxicity in lean human subjects and 
significantly increased smoke reduced IFNγ production. Further, it was shown to restore 
smoke reduced NK cell activation and cytotoxicity through enhancing the release of cytotoxic 
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1.5 Aim of the Study 
Various studies with APN-KO mice revealed the anti-inflammatory role of APN in several 
disease models moderating the course of disease. The effect of APN on monocytes and 
macrophages, members of the innate immune system, as well as on epithelial cells has been 
extensively analyzed but little has been known so far about the modulating actions of APN on 
lymphocytes.  
The aim of the study was to assess the function and molecular mechanism of APN on T and 
NK cells. 
The specific objectives were as follows: 
 
 ● The analysis of AdipoRs expression on human and murine T and NK cells including 
their regulation 
 
 ● The study of the effects of APN on activated T cells and their functions with regard 
to the generation of antigen activated T cells, apoptosis, proliferation and cytokine 
responses 
 
 ● The study of the effects of APN on stimulated NK cells including cytotoxicity and 
cytokine response 
 
 ● The investigation of in vivo T and NK cell responses in APN deficient mice upon 













2 MATERIAL  
2.1 Subjects 
2.1.1 Human 
Human peripheral blood was collected from healthy volunteers. Bone marrow cells were 
collected from femoral head of donors who underwent operation. Studies were approved by 
the Institutional Ethics Committee and informed consents were obtained from the subjects.  
 
2.1.2 Animal Model 
APN-KO mice, which carry a deletion of the adiponectin gene, on a C57BL/6 background 
and C57BL/6 wild-type (WT) mice were purchased from Jackson laboratories. All mouse 
strains were bred in the Forschungsinstitut für Experimentelle Medizin (Berlin, Germany). 
WT and APN-KO mice, aged 8 to 10 weeks, were inoculated with Coxsackie virus B3 
(CVB3) (Nancy strain, 5- 10
5
 plaque-forming units ip) diluted in 0.2 ml saline as previously 
described [110]. Three and seven days after viral infection, mice were sacrificed and 
splenocytes and blood were aseptically removed. 
 
2.1.3 Cell lines 

















Tab. 1: Cell lines 































lymphoblast, Leukemia, acute T cell; T lymphocyte 
suspension 
Immortalized line of T lymphocytes that are used to study acute T cell 
leukemia. Their primary use, however, is to determine the mechanism 







lymphoblast, chronic myelogenous leukemia 
suspension 
The cells spontaneously differentiate into precursors of the erythroid, 
granulocytic and monocytic series. The line is EBNA negative. 
 
YAC-1 





Moloney murine leukemia virus (Mo-MuLV) induced lymphoma. The 
cells are sensitive to the action of NK cells and are useful in assays of 
NK cell activity.  
 
 






2.2.1 Cell isolation and separation reagents 
Mononuclear cells from human and murine blood or spleen were separated with Biocoll 
(Ficoll) separating solution (density 1.077g/ml) (Biochrom AG, Germany) or Histopaque 
1083 separating solution (density 1.083g/ml) (Sigma Aldrich Inc., USA). To obtain single cell 
suspension spleens were filtered through 70µm nylon meshes (Becton Dickinson GmbH, 
USA). Murine blood was treated with red blood cell lysis buffer (ACK buffer). Cells were 
washed consistently with human or murine FACS buffer.  
 
2.2.2 Kits 
Human T cells were depleted by CD3 MicroBeads (positive selection) or isolated by Human 
Pan T cell isolation kit II (negative selection) (Miltenyi Biotec, Germany). Human NK cells 
were isolated by NK cell isolation kit (Miltenyi Biotec). If not differently described human T 
cells were activated with T cell Activation/Expansion kit containing CD3/CD28 beads 
(Miltenyi Biotec). RNA was extracted using RNeasy Mini Kit (Qiagen, Germany) and reverse 
transcribed with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Germany). Real-time quantitative PCR was performed using TaqMan
®
 Universal PCR Master 
Mix (Applied Biosystems) and corresponding primer sets (s. 2.2.4 Assays).  
Apoptosis was detected by using FITC Annexin V Apoptosis Detection Kit I (Becton 
Dickinson) and proliferation by BrdU Flow Kit® (Becton Dickinson GmbH). Cytotoxicity 
was determined with LIVE/DEAD® Cell-mediated Cytotoxicity Kit (L7010, Invitrogen 
Corporation, USA). Assays were performed according to the manufactures instructions. 
 
2.2.3 Cell culture media 
Isolated human PBMCs, sorted T and NK cells were incubated and cultured in Iscove's 
Modified Dulbecco's Medium, (IMDM, PAA Laboratories, Austria), containing 10% heat-
inactivated human AB serum (Valley Biomedical Inc., USA), 2mM glutamine and 1% 
Penicillin/Streptomycin (PAA Laboratories). Isolated splenocytes, murine cells and cell lines  
 





were held in Roswell Park Memorial Institute medium (RPMI 1640, PAA Laboratories), 
supplemented with 10% heat-inactivated FCS (PAA Laboratories), 2mM glutamine, 1% 
penicillin/streptomycin. The culture medium of murine cells was supplemented with 500U/ml 
IL-2. RPMI 1640 medium was used as freezing medium containing 10% DSMO and 40% 
serum.  
 
2.2.4 Primers for qRT-PCR 




 Gene Expression Assays for:  
human AdipoR1 (Hs00360422_m1),  
human AdipoR2 (Hs00226105_m1),  
human 18s rRNA (Hs99999901_s1) 
murine Nkp46 (Mm00456776_g1) 
murine IFN-γ (Mm01168134_m1)  
 
2.2.5 Antibodies  
Antibodies were used for flow cytometry or immunofluorescence staining for successive 
confocal microscopy. All antibodies, accept AdipoR1 and AdipoR2, against human antigens 
were raised in mice. AdipoR1 and AdipoR2 were raised in rabbit.  















Tab. 2: Antibodies with human specificity 
Antigen Clone Dilution Company 
AdipoR1 polyclonal 1:300 Phoenix Pharmaceuticals, USA 
AdipoR2 polyclonal 1:300 Phoenix Pharmaceuticals 













Becton Dickinson GmbH 
Becton Dickinson GmbH 
Becton Dickinson GmbH 










Influenza tetramer A2 























Becton Dickinson GmbH 
Becton Dickinson GmbH 
kindly provided by Nalan Utku, 
Becton Dickinson GmbH 
 
Becton Dickinson GmbH 
Becton Dickinson GmbH 
Becton Dickinson GmbH 
Becton Dickinson GmbH 



















Tab. 3: Antibodies with murine specificity 
Antigen Clone Dilution Company 
CD45 30-F11l 1:100 eBioscience Inc., USA 
CD3e 145.2C11 1:100 eBioscience Inc. 
CD4 GK1.5 1:200 eBioscience Inc. 


































Becton Dickinson GmbH 
Becton Dickinson GmbH 
BioLegend 
 
Tab. 4: Secondary antibodies 
Antibody Fluorochrome Dilution Company 
Goat anti rabbit mAb (GAR) Alexa Fluor
®
 488 1:400 Invitrogen Corporation 
Goat anti mouse mAb (GAM) Cy
TM
 3 1:100 Jackson ImmunoResearch, USA 
 
2.2.6 Fluorescence dyes 
Tab. 5: Fluorescence dyes 
Dye Company 
Live Dead-Pacific Blue 
DAPI 
Invitrogen Corporation 











2.2.7 Stimulating and activating agents 
2.2.7.1 Recombinant proteins and cytokines 
Tab. 6: Recombinant proteins and cytokines 











R&D Systems Inc., USA 
Chiron, Great Britain 





2.2.7.2 Toll-like receptor agonists and other stimuli 
Tab. 7: Toll-like receptor agonists and other stimuli 
Toll-like receptor agonist/stimuli Final concentration Company  
LPS from E. coli S form for TLR 4 
R848 for TLR-8 
SEB 
PHA-L 








ALEXIS Biochemicals, Swiss 
ALEXIS Biochemicals, Swiss 
Sigma Aldrich Inc. 
Sigma Aldrich Inc. 




2.2.8 Chemicals, Solution and Buffers 




Baxter GmbH, Germany 
Sigma Aldrich Inc.  
BSA Sigma Aldrich Inc. 
BD CompBeads, anti-mouse Ig 
BD Lyse 
BD Perm 
Becton Dickinson GmbH 
Becton Dickinson GmbH 
Becton Dickinson GmbH 












PBS without Ca and Mg 
Trypanblue 
Sigma Aldrich Inc. 
BioTest AG, Germany 
PAA Laboratories 
Sigma Aldrich Inc. 
Merck KGaA,  
Southern Biotech, USA 
PAA Laboratories 
Merck KGaA;  
 
Tab. 9: Buffers 
Name Ingredients 
ACK buffer 0.15 M NH4Cl, 
0.01M KHCO3, 
0.07 mM EDTA in H20 
FACS buffer human PBS with 2% FleboGamma 
FACS buffer murine 
MACS buffer 






Among the current laboratory equipment the following hardware was used.  
Tab. 10: Equipment 
Type Company 
Cell strainer 70µm 
Centrifuge 5415D 
Becton Dickinson GmbH 
Eppendorf AG, Germany 
FACS Canto II analyzer 
FACS LSR II analyzer 
FACS tubes 
GeneAmp PCR System 9700 
Beckton Dickinson GmbH 
Beckton Dickinson GmbH  
Beckton Dickinson GmbH  
Applied Biosystems 





Continuation Tab. 10: Equipment 
Heraeus Multifuge 3SR+ 
Leica TCS SP5 confocal microscope 
NanoDrop ND 1000 
Neubauer counting chamber 
Microscope BX 300 
Superfrost ultra plus slides 
Thermo Fisher Scientific Inc., USA 
Leica Microsystems GmbH, Germany 
Thermo Fisher Scientific Inc.  
Lo Laboroptik, Germany 
Will Wetzler, Germany 
Thermo Electron LED GmbH, Germany 
Vacutainer blood collection system Beckton Dickinson GmbH 
 
2.4 Software 
Flow cytometry data were generated by BD FACSDiva software v6.0 and analyzed with 
Flow.Jo v9.4.1.0 (Treestar). Leica LAS AF Lite Software was used by Jordi Magrane and 
Diana Elligsen-Merkel to evaluate and quantify confocal fluorescence microscopy images. 
RNA quality and quantity was estimated using NanoDrop software. Real-Time PCR data 
were analyzed by 7500 sequence detection software (SDS) v1.4. Besides Microsoft Office 
2010 (Microsoft), statistical analysis and calculations were performed by Graphpad Prism.  
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3 METHODS 
3.1 Cell culture and preparation 
3.1.1 Isolation of human peripheral blood mononuclear cells (PBMCs) 
Blood was collected using the BD Vacutainer blood collection system. Blood was diluted 1:1 
with PBS and separated under sterile conditions by gradient centrifugation using Ficoll with 
850 g for 20 minutes at room temperature (RT) without brake. The PBMC fraction was 
collected, diluted 1:1 with PBS, centrifuged at 400 g for 10 minutes at RT and resuspended in 
IMDM medium containing 40% AB serum. Cells were counted using the Neubauer counting 
chamber and trypan blue for discriminating alive cells. 
 
3.1.2 Isolations of human CD3 T cells 
Isolation of human T cells was performed using MACS
®
 Pan T cell isolation kit II (negative 
selection) or CD3 MicroBeads (positive selection) according to the manufactures instructions 
from PBMCs. In summary, negative selection was performed by depletion of non-T cells 
whereas during positive selection T cells were labeled with CD3 MicroBeads.   
 
3.1.3 Isolation of human NK cells 
Human NK cells were isolated from PBMCs using the MACS
®
 NK cell isolation Kit. 
Separation was performed as described by the manufactures’ instruction. Briefly, all non-NK 
cells were magnetically labeled and isolated from the PBMCs over a MACS
®
 Column placed 
in a magnetic field. Non-NK cells were retained on the column while the untouched NK cells 
pass through.. 
 
3.1.4 Isolation of murine splenocytes and peripheral cell 
Mice were sacrificed by isoflurane inhalation at indicated time points. Spleens and blood were 
aseptically removed. Heparinized blood was treated three times with ACK buffer to remove 
red blood cells. Single cell suspensions were made by splashing the spleen through a 70 µm  
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cell strainer and diluting the suspension in cold PBS. All obtained cells were counted and 
cultured in RPMI culture medium containing L-glutamine, supplemented with 10 % FCS, 1% 
each of penicillin/ streptomycin and 500U IL-2 at 37°C with 5% CO2, or used immediately 
after washing and resuspending in FACS buffer. Absolute murine NK cell numbers were 






3.1.5 Thawing of cell lines 
Frozen cells were stored in cyroconservation tubes in liquid nitrogen. 20 mL of 37°C warm 
Iscoves medium with 4% AB serum were prepared and 1 mL of frozen cell suspension was 
diluted stepwise with the warm culture medium. The 20 mL solution containing the thawed 
cells was washed and finally resuspended in PBMC culture medium (Iscoves with 10% AB 
serum). 
 
3.1.6 Freezing of cells 
For long term storage in liquid nitrogen cells were frozen in freezing medium. 1ml of freezing 
medium was used to resuspend 10
7
 cells in ice-cold cyroconservation tubes. Freezing 
container was used to store cells in -80°C before transferring to the nitrogen tank.  
 
3.2 Stimulation  
3.2.1 Stimulation of T cells 
Functional analyses of T cells were performed on PBMCs rested overnight. Antigen activated 
T cells were generated from PBMCs following stimulation with SEB or influenza peptide in 
96 well plates in the presence of rhIL-2 and rhIL-7. PBMCs were seeded in 200µl of medium 
at concentrations of 2 x 10
5
 per well and analyzed at various time points after stimulation. 
APN was added 24h before stimulation. Activated and antigen specific T cells were 
determined by CD137 surface expression, cytokine production and by tetramer staining. 
Expansion of influenza specific T cells determined by cytokine response was analyzed at day 
9 of culture upon 6h restimulation with influenza peptide. BFA was added at the last 4h of 
restimulation. Antigen specific T cell cytokine production was measured in freshly isolated 
PBMCs following 24h stimulation with influenza peptide. BFA was added at the last 22h. 
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3.2.2 Stimulation of NK cells 
For NK cell stimulation PBMCs and sorted NK cells from healthy donors were primed with 
rhIL-12 and preincubated with APN for 24h. Sorted NK cells were seeded in 200µl of 
medium at concentrations of 2.5 x 10
5
 per well in 96 well plates. Stimulation was performed 
with the Toll-like receptor (TLR) ligands LPS and R848 for additional 24h. BFA was added 
at the last 6h of stimulation. Intracellular IFN-γ production of NK cells was analyzed via flow 
cytometry.  
 
3.3 Flow cytometry 
3.3.1 Staining procedures  
Cells were harvested and washed with FACS buffer. 1mM EDTA/PBS was added for 10min 
at room temperature. Before the addition of antibodies the cells were washed. Extracellular 
cell markers were stained for 20min at 4°C, washed and resuspended in FACS buffer.  
Intracellular molecules were stained after the extracellular staining procedure. Therefore cells 
were washed in 1x BD Lyse to remove red blood cells and permeabilized with 1x BD Perm. 
Intracellular staining was performed 30min at 4°C. Finally, cells were washed and 
resuspended in FACS buffer.  
AdipoRs staining was performed using fluorescence labeled goat anti rabbit secondary 
antibody. AdipoRs staining was performed prior to CD antigen staining except in case of 
intracellular staining of the receptors.  
 
3.3.2 Gating strategies 
For the expression analysis of AdipoR1 and AdipoR2 dead cells and “cell doublets” were 









 NK cells, CD14 monocytes and 





and AdipoR2 expression was studied on indicated PBMCs subsets. Activated and antigen 
specific T cells were identified by CD137 and cytokine expression as well as by influenza 
matrix protein 58-66 tetramers.  
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populations whereas NK cells were defined by the absence of CD3e and the expression of 
Nkp46 and DX5. CD45 was used to identify leukocytes in isolated murine blood. NK cells 
were further divided using the maturation markers CD11b and CD27. CD94 and NKG2D 
were used to characterize effector NK cells. Intracellular IFNγ staining was used to analyze 




 splenocytes. AdipoRs expression was analyzed on 
different murine cell subsets.  
 
3.4 Confocal microscopy 
Confocal microscopy was used to analyze the localization of AdipoRs with cytoplasmic 
compartments and molecules. After PHA-L stimulation, CD3 cells, isolated with Pan T Cell 
Isolation Kit II (Miltenyi Biotech) were intracellular stained for AdipoRs visualized by Alexa 
Fluor
®
 488 conjugated goat-anti rabbit antibody and co-stained against clathrin heavy chain, 
CTLA-4 and TIRC7. Clathrin, CTLA-4 and TIRC7 were visualized by Cy3-conjugated anti 
mouse antibody. Cells were fixed with 2% formalin in PBS, adhered to glass slides by 
centrifugation via cytospin and mounted.  
Confocal analysis of clathrin-coated vesicles, CTLA-4 and AdipoRs was performed by Jordi 
Magrane from Weil Medical Collage of Cornell University. Images were collected in a Leica 
Confocal Microscope using a 63 oil immersion lens (NA1.4), standard pinhole of 1 AU, and 
optical intervals of 0.4 mm; a 2.5 zoom was applied. Standard 488 and 543nm excitation 
wavelengths were used for the detection of Alexa488 and Cy3.  
Confocal fluorescence microscopy of AdipoRs and TIRC7 localization was done by Diana 
Elligsen-Merkel from CellAct Pharma GmbH used. Leica fluorescence microscope DMI 4000 
B. Confocal microscopy was performed as described in [94].  
 
3.5 Quantitative Real-Time-PCR 
Quantitative Real-Time-PCR was used to determine AdipoR mRNA levels in human T cells 
and CD3 depleted cells, as well as Nkp46 and IFNγ mRNA expression levels in murine 
splenocytes. CD3 T cells were separated from PBMCs by pan T-cell isolation kit II (negative 
selection) or by CD3 MicroBeads (positive selection). Total RNA from murine splenocytes,  
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human CD3 cells or CD3-depleted PBMCs was extracted and reverse transcribed into cDNA 
using High-Capacity cDNA Reverse Transcription Kit according to the manufactures 
description. Quality and quantity were checked by Agilent 2100 Bioanalyzer. Real-time 
quantitative PCR was performed using TaqMan
®
 Universal PCR Master Mix. Evaluation was 
performed by DDCt method.  
 
3.6 Assays 
3.6.1 Analysis of proliferation and apoptosis 
Human antigen specific T cells were generated from PBMCs by CD3/CD28 activation using 
T cell Activation/Expansion kit or by stimulation with influenza peptide. 72h after 
stimulation, APN was added to the culture for additional 24h and the frequencies of 
proliferating and apoptotic antigen specific cells were assayed by flow cytometry using BrdU 
Flow Kit
® 







3.6.2 CD107a degranulation assay 
NK cell degranulation of human and murine NK cells was measured by CD107a secretion 
[111]. Human PBMCs were stimulated with rhIL-2 (100U/ml), APN (3µg/ml) or 
simultaneously with IL-2 and APN for 20hours and incubated with K562 target cells at an 
effector to target ratio of 1:1 and 1:2. Sterile mAb against CD107a was added to cells, 
cultured for one hour at 37°C and incubated with 2mM monensin to prevent intracellular 
protein transport. Five hours later cells were stained with mAb against CD3, CD8 and CD56 
and analyzed by flow cytometry. Dead cells were excluded from analysis.  
Murine splenocytes from uninfected and CVB3 infected mice were incubated in the presence 
of 500U/ml rmIL-2 with YAC-1 target cells at an effector to target ratio of 50:1 and 100:1 
and incubated with CD107a antibody. One hour later 7.5µg/ml brefeldin A was added to the 
culture. Cells were cultured for a total time of four hours, harvested, stained for CD3e, CD8a 
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3.6.3 In vitro killing assay 
Cytotoxicity of human NK cells was measured by the LIVE/DEAD
®
 Cell Mediated 
Cytotoxicity Kit (Invitrogen). K562 target cells were labeled in a dilution of 1:100 with the 
3,3’dioctadecylloxacaebocyanin fluorescence dye for 30min, washed twice with PBS and 
incubated with sorted NK cells at effector to target ratio of 1:1 and 1:4. Cells were treated 
with 3µg/ml APN and/or 100U/ml IL-2 and cultured with the provided propidium iodid (PI) 
solution for three hours at a dilution of 1:400. Cells were analyzed using flow cytometry.  
 
3.7 Statistical analysis 
Analysis of human data was performed using one-tailed Wilcoxon signed rank test. 
Significance of mice data were calculated by one-tailed Mann-Whitney –U test. All graphs 
are shown as mean ± SD or SEM. 
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4 RESULTS 
4.1 Immunomodulatory effects of APN on T cells 
4.1.1 AdipoRs expression and localization in human T cells 
To study the effects of APN on T cells we first analyzed the expression of both AdipoRs on 
human peripheral blood T cells of healthy donors by flow cytometry. Consistent with 
published data, ex vivo surface receptor staining revealed that only a small fraction of CD3
+
 T 
cells expose AdipoR1 and AdipoR2 on their surface. Whereas almost all human CD14
+
 









 (mean 7,5% for 
AdipoR1 and 7,3% for AdipoR2) T cell subpopulations (Fig.7A).  
 
Figure 7:  AdipoRs expression on human CD3
+
 T cells. (A) Surface expression on CD14
+
 monocytes and T 
cell subpopulations assessed by flow cytometry. Represented are the frequencies of AdipoR1 and 
AdipoR2 expression on the respective PBMC subpopulation (n=6; mean±SD). (B) AdipoRs mRNA 
expression levels in CD3
+
 T cells and CD3 depleted PBMCs. mRNA levels of AdipoRs of cell 
fractions received by negative and positive magnetic selection are depicted relative to 18S rRNA 
transcription (negative selection n=4, positive selection n=3; mean±SEM). Published in [112]. 
 
In contrast, the measurement of AdipoR1 and AdipoR2 mRNA levels by quantitative Real-
Time PCR (RT-PCR) illustrated that CD3
+
 T cells express almost half the amount of both 
receptor transcripts when compared with CD3 depleted PBMCs (Fig.7B). To exclude changes 
in the AdipoRs mRNA transcription dependent on the CD3 selection method we performed  
quantitative assessment of both receptors by using negatively and positively separated CD3
+
 
T cells. In both cases results were similar independent of the isolation method and showed  
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high receptor’s transcript levels in CD3+ T cells conflicting with the flow cytometry data. 
According to this, intracellular (i.c.) flow cytometry staining of AdipoRs were performed on 
peripheral blood CD3
+
 T cells. Figure 8 depicts the comparison between the surface and 
intracellular expression of AdipoR1 in CD3
+
 T cells and CD14
+
 monocytes. While AdipoR1 
was expressed on the surface (e.c.) of most monocytes, CD3
+
 T cells showed mainly an 









 T cell subsets (data not shown).  
 
 
Figure 8: Intracellular (i.c.) and extracellular (e.c.) expression of AdipoR1 in peripheral blood CD3
+
 T 
cells (left) and CD14
+
 monocytes (right). One representative staining with AdipoR1 specific mAb 
is shown. GAR indicates negative control stained with goat-anti rabbit secondary Ab for visualizing 




 T cells originate from lymphoid precursors in the bone marrow and are able to re-
enter it during their life spam we analyzed the AdipoRs distribution on bone marrow T cells 
being exposed to a different microenvironment than peripheral blood T cells. Similar to T 
cells in the blood stream bone marrow T cells displayed only low frequencies of extracellular 




 T cells whereas intracellular expression was 




 T cells (Fig. 9A). In contrast to CD19
+
 B cells (Fig. 9B) 
and CD14
+
 monocytes (Fig. 9C) found in bone marrow which all exposed the receptors on the 
surface.  
In line with the expression pattern of AdipoRs on T cells the expression of both receptors on 
the T lymphatic leukemia cell line Jurkat was limited to the cytoplasm whereas the myeloid  
leukemia cell line K562 demonstrated high extracellularly AdipoR1 and Adipor2 expression 
(Fig. 10).  
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Figure 9: Intracellular (i.c.) and extracellular (e.c.) expression of AdipoR1 and AdipoR2 on bone 





cells, (B) bone marrow CD19
+
 B cells and (C) in bone marrow CD14
+
 monocytes. GAR indicates 




Figure 10:  Intra- and extracellular expression of AdipoRs on lymphatic leukemia cell line Jurkat and 
myeloid leukemia cell line K562. Representative staining of AdipoRs is shown. GAR indicates 
negative control, numbers frequencies of positive cells. Published in [112].  
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Given that the majority of CD3
+
 T cells express AdipoRs intracellularly and APN was shown 
as an inhibitory protein in cells of the innate immune system we hypothesized that AdipoRs 
might be stored like other T cell regulatory molecules in cytoplasmatic compartments. After 
isolation of PHA stimulated peripheral blood T cells and intracellular staining of AdipoRs, 
CD3
+
 cells were co-stained against TIRC7, CTLA-4 and clathrin, a marker for clathrin-coated 
vesicles. Fluorescence labeled cells were counterstained with DAPI to exclude cell debris and 
adhered to glass slides. Localization was visualized by confocal fluorescence microscopy. As 
shown in Figure 11 staining of AdipoRs and TIRC7 defined by green and red fluorescence, 
respectively, revealed a co-localization of both structures near the cell surface of T cells 
resulting in a yellow fluorescence after overlay of both pictures. However, AdipoR2 
illustrated a weaker co-localization with TIRC7 compared with AdipoR1 and TIRC7. Further 
similar analyses were performed to study the localization of AdipoR1 in clathrin-coated 
vesicles and with CTLA-4 within CD3
+
 T cells. Staining with specific anti-AdipoR1, anti-
clathrin and anti-CTLA-4 mAb demonstrated a co-localization of AdipoR1 and CTLA-4 (Fig. 
12D), as well as clathrin. (Fig. 12A, B). Orthogonal sections across the z-image stack from 
the cells shown in Fig12A (dotted area) represent strong cellular association of AdipoR1 and 
clathrin near the plasma membrane. The quantitative analysis of co-localization using single 
optical plane taken at the mid-section of a cell revealed a Pearson’s correlation coefficient 
R(r) = 0.69±0.11. The Pearson's correlation coefficient between AdipoR1 and CTLA4 was 
R(r) = 0.43 ±0.11. These results depicted that the majority of T cells express the AdipoRs 
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Figure 11: Intracellular co-localizations of AdipoRs with TIRC7 in human T cells. Staining of AdipoR1 
and AdipoR2 (green) and TIRC7 (red) labeled cells was detected by confocal fluorescence 
microscopy. Dotted areas indicate co-stained, yellow structures (scale bar 20µm) taken and shown 
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Figure 12: Intracellular co-localization of AdipoR1 with clathrin-coated vesicles and CTLA-4. 
Immunofluorescence staining was detected by confocal microscopy of CD3
+
 T cells. (A) General 
view in a merged z-image stack and (B) single optical planes (z-section, 0.4µm thick) taken at the 
mid-section of the cells are shown (scale bars 10µm). (C) Orthogonal sections across the z-image 
stack from the cells shown in (A) dotted area (scale bars 5µm). (D) General view of the cells. Dotted 
area indicates co-stained structures (magnification, 63x). One representative co-staining is shown. 
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4.1.2 AdipoRs Expression on murine T cells 
Next we analyzed expression patterns of AdipoRs in murine T cells. Therefore mice 
splenocytes of male C57BL//6 WT mice aged 8-10 weeks were removed, stained for CD3e 
characterizing T cells, and analyzed for AdipoRs distribution by flow cytometry. Similar to 
human T cells analysis revealed that both receptors are predominantly expressed intracellular 
(Fig. 13). Only a minor fraction of freshly isolated murine splenic T cells displayed AdipoRs 
on the cell surface. Whereas the intracellular staining showed that more than 90% of T cells 
store the receptors in the cell plasma solely <15% expose AdipoR1 and AdipoR2 on the cell 
surface (Fig. 13 and 14).  
 
Figure 13:  Distribution of AdipoRs in murine CD3e
+
 T cells. Representative dot plots of extra- (e.c.) and 
intracellular (i.c.) staining of AdipoRs in murine T cells are shown. GAR indicates negative control 
and numbers the percentages of positive cells.  
 
For functional analysis of APN effects we also used APN-KO mice. Intra- and extracellular 
staining of both receptors on T cells from APN-KO mice showed no differences in the 
expression pattern of AdipoRs compared to WT mice (Fig. 14). Surface AdipoR1 and 
AdipoR2 expression was detected on a minor fraction of T cells, respectively, whereas 
receptor expressions were identified in the cytoplasm of >90% of T cells of APN-KO mice. 
Thus, the absence of APN in the APN-KO mice had no influence on the expression pattern of 
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Figure 14:  Expression of AdipoRs on murine CD3e
+
 T cells of WT and APN-KO mice. Represented are 
frequencies of AdipoR1 (black bars) and AdipoR2 (grey bars) on ex vivo T cells analyzed by flow 
cytometry. AdipoRs were stained extra- (e.c.) and intracellular (i.c.) (mean±SEM; n=5).  
 
4.1.3 AdipoRs regulation on T cells 
Analysis of the potential function of APN on T cells requires the knowledge about the 
regulation of AdipoRs. To elucidate the regulation of AdipoRs T cells were first stimulated 
with Staphylococcal enterotoxin B (SEB) to generate antigen reactive T cells.  
 
 




 T cells. Surface expression of 
(A) AdipoR1 and (B) AdipoR2 was analyzed on activated T cells detected by CD137 expression at 
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SEB is known as a superantigen. It activates a large number of T cells because it is not 
processed and presented via MHC class II binding groove but cross-links MHC class II to the 
TCR therefore causing polyclonal T cell activation which can be detected by CD137 





 T cells characterized by CD137 upregulation at various time points of SEB 







 T cells (Fig. 15A and B) however, AdipoR1 revealed higher expression 












 T cells upregulated the inhibitory molecule CTLA-4 within 48h of SEB incubation 
whereas expression on CD137
-
 T cells was not detectable (Fig.16).  
 
 
Figure 16: Co-expression of AdipoR1 and CTLA-4 on human CD137
+
 T cells. FACS data illustrating (A) 






 T cells (n=6) and (B) the 
co-expression of AdipoR1 and CTLA-4 on CD137
+
 CD8+ T cells (n=4) at various time points of 
SEB stimulation. Numbers indicate percentages of positive cells. Published in [112]. 
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In accordance to the fluorescence microscopy data CTLA-4 expression correlated with the 
upregulation of AdipoRs (AdipoR2 not shown) on the surface of antigen specific T cells (Fig. 










 T cells and AdipoR2 on CD8+ and CD4
+
 T cells (data not 
shown).  
To confirm these results we performed additional experiments with short term T cell lines 
generated against a HLA-A2-binding influenza peptide. At day 9, two days after restimulation 
with influenza matrix protein, antigen specific T cells were detected by influenza tetramer 
displaying frequencies of 12.1% as shown in Fig 17. HIV tetramer staining was used as a 
negative control (0.1%). Co-staining revealed that the majority of influenza tetramer positive 
CD8
+
 T cells co-expressed AdipoR1 (83%) whereas only a minor population of the influenza 
negative cells expressed AdipoR1 on their surface (8.41%). 13% of T cells expressed CD137 




 T cells revealed that almost 70% of them 
are influenza specific T cells and 86.4% of the influenza specific T cells expressed surface 




, but influenza negative T cells showed also 
an AdipoR1 expression. Influenza expanded cells stained with HIV tetramer showed also 13% 
of activated CD137
+
 T cells not specific for influenza. 56% of CD137
+
 T cells expressed 
AdipoR1 surface receptor.  
 
Figure 17: AdipoR1 surface expression on influenza activated human T cells detected by tetramer 
staining. Representative dot plot of influenza specific T cells visualized by tetramer staining at day 
nine is shown. Majority of influenza specific T cells express AdiopoR1. Co-expression of influenza 




 T cells. HIV tetramer staining served as a 
negative control (upper panel). Numbers indicate percentages of positive cells. Data were obtained 
by flow cytometry. Partially published in [112]. 
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Raised short term influenza specific T cell lines were additionally characterized by IFNγ 
production on day 6 after 6 hours of restimulation with influenza peptide. Controls were 
restimulated with HIV peptide (Fig. 18).  
 
 
Figure 18: AdipoR1 surface expression on influenza activated human T cells detected by IFNγ staining. 
Shown are representative dot plots of influenza specific T cells visualized by IFNγ staining at day 
six. (A) Influenza specific T cells restimulated with HIV. Cultures served as negative controls for 
cytokine staining (B) Influenza specific T cells restimulated with influenza peptide. Numbers 
indicate percentages of positive cells. 
 
As shown in Figure 18B 6.1% of CD8
+
 T cells in the generated cultures expressed IFNγ. Co-
staining revealed that 61% of IFNγ producing T cells expressed surface AdipoR1 whereas 
only 9.7% of IFNγ- CD8+ T cells exposed AdipoR1 on the cell surface. Controls restimulated 
with HIV peptide showed no IFNγ production but displayed a minor fraction of 4.5% IFNγ- 
CD8
+




 T cells expressed IFNγ and 
were characterized as influenza specific T cells which exhibited 76% of surface Adipor1 
expression. Summarized, AdipoRs are upregulated upon antigen activation on antigen specific 
and antigen activated CD137
+
 T cells 
To evaluate the dynamics of AdipoR1 surface upregulation on antigen specific T cells, 
extracellular expression of AdipoR1 was determined on influenza specific CD8
+
 T cells 
assayed by CD137 expression 24h up to nine days after peptide stimulation (Fig. 19). 




 T cells within 72h of stimulation.  
Surface expression was increased after 48h of stimulation and could by detected until day 




 T cells whereas extracellular expression of AdipoR1 
on CD137
-
 T cells was not induced. 
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 influenza activated T cells. AdipoR1 expression was detected by flow cytometry 
following influenza peptide stimulation (n=4). Published in [112].  
 
Similar to human T cells resting murine T cells of WT and APN-KO mice revealed 
predominantly intracellular AdipoRs expression (Fig. 14), Coxsackie virus B3 (CVB3) 
infection induced an upregulation of both receptors in WT and APN-KO animals on the cell 
surface (Fig. 20). AdipoR1 was detected on mean 30%, AdipoR2 on mean 40% of murine T 
cells. There was no difference in the fold induction of receptor expression between WT and 
APN-KO mice.  
 
 
Figure 20: Regulation of AdipoRs on murine T cells. Surface expression of AdipoR1 (black bars) and 
AdipoR2 (grey bars) was analyzed by flow cytometry on T cells of uninfected and infected WT and 
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4.1.4 Functional Effects of APN on T cells 
Next we studied the effects of APN on generation, proliferation and cytokine production on 
antigen specific T cells. Influenza specific T cell lines were raised from PBMCs in the 
presence or absence of APN added together with influenza peptide (Fig. 21). The cell 
numbers of influenza specific T cells were identified by CD8 and CD137 staining at various 
time points analyzed by flow cytometry. Whereas total cell counts of the cultures were not 
impaired by the presence of physiological concentrations of APN (+APN: mean 1.6 x 106; -




 T cells were diminished in the 
presence of APN at day 6 and day 9 (Fig. 21).  
 
 
Figure 21: Influence of APN on the generation of human antigen specific T cells. Counts of influenza 
specific T cells assayed by CD8 and CD137 staining and analyzed by flow cytometry. Cell numbers 
were determined in the absence (black squares) and presence (white squares) of APN at the 
indicated time point (n=6; *p<0.05 for days 6 and 9). Published in [112]. 
 
AdipoRs expression was, however, not influenced by APN (Fig. 22). Measurement of surface 
AdipoR1 expression after 24h, 48h and 72h of SEB stimulation revealed no impact of APN 






 T cells. In accordance, lower numbers of 
antigen specific, cytokine producing T cells were detected at day 9 in cell lines raised in the 
presence of APN (Fig. 23 left). Following six hours of restimulation with influenza peptide at 
day 9 the numbers of IFNγ-, TNFα- and IL-2-producing cells were significantly decreased in 






  Results 
 
  48 
 
 
Figure 22: Influence of APN on AdipoR1 expression of SEB activated T cells. Frequencies of AdipoR1 
expression following SEB stimulation on total (upper panel) and CD137
+





 T cells. PBMCs were stimulated in the presence (grey lines) and absence (black lines) of APN 
(n=3). Data shown are mean±SEM.  
 
 
Figure 23:  APN impact on cytokine producing human CD8
+
 T cells and on ex vivo cytokine production. 
(Left) Numbers of influenza specific T cells determined by IFNγ, TNFα and IL-2 production in the 
absence (black bars) and presence (grey bars) of APN were detected by intracellular cytokine 
staining (n=6; *p<0.05). (Right) Frequencies of influenza specific T cells producing IFNγ and TNFα 
in response to 24h peptide stimulation in freshly isolated PBMCs in the absence (black bars) and 
presence (grey bars) of APN (n=7; **p<0.01). Data presented are mean±SD. Published in [112]. 
 
Further, the direct effect of APN on specific T cell cytokine production was studied ex vivo. 
Therefore freshly isolated PBMCs were preincubated with APN and stimulated with influenza 
peptide for 24h. Influenza specific T cell responses were assessed by cytokine production of 
CD8
+
 T cells detected by flow cytometry (Fig. 23 right). Frequencies of influenza specific 
IFNγ as well as TNFα producing CD8+ T cells were diminished in the presence of APN.  
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These data show that APN exerts a direct inhibitory effect on antigen-induced cytokine 
production. 
To study the inhibitory molecular mechanism of APN on the generation of antigen activated T 
cells we analyzed the influence of APN on apoptosis and proliferation. The impact on both 
processes was assayed in CD3/CD28 polyclonal activated human T cells. BrdU incorporation 





determined by flow cytometry. As shown in Figure 24, APN had no effect on the proliferation 
and apoptosis of CD137
-
 T cells whereas apoptotic cell death was increased in CD137
+
 T cells 
(Fig. 24A).  
 
 





T cells was assayed by annexin staining and measured by flow 
cytometry. Percentages of apoptotic cells in the absence (black bars) and presence (grey bars) of 




T cells was determined by BrdU 
incorporation and flow cytometry. Impact of APN on proliferation is shown by grey bars. (n=6; 
*p<0.05; NS-not significant). Data shown are mean±SD. Published in [112]. 
 
In line with the pro-apoptotic effect, APN inhibited the proliferation of CD137
+
 T cells (Fig. 
24B) but not of CD137
-
 T cells. Similar but less pronounced results were obtained using 
influenza specific CD137
+
 T cells (Fig. 25). In the presence of APN significantly higher 




 T cells were detected on day 4 as compared to non-
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Figure 25: APN influence on apoptosis and proliferation of human influenza activated T cells. Frequencies 




 T cells analyzed by flow cytometry. 
Black bars indicate cultures in the absence of APN and grey bars show results of cultures incubated 
with APN. Data shown are mean±SEM (Annexin n=7; **p<0.01; BrdU n=3; NS-not significant). 
 
To determine whether the presence of APN attenuates the antigen activated T cell response in 
vivo, we comparatively analyzed the T cell response in CVB3 infected APN-KO and WT 
mice. T cell responses, defined as frequencies of CD137+ cells, were analyzed at day 3 and 7 
after infection (Fig. 26).  
 
 









 T cells of infected WT and APN-KO mice were determined by flow 
cytometry. Splenocytes were isolated on day 3 and 7 after infection Data shown are mean±SEM 
(n=5; *p<0.05). Published in [112].  
 









 (Fig. 26B) T cells were significantly higher in APN-KO mice as compared to WT 
mice on day 7of infection 
In summary, APN negatively influenced the generation of antigen specific T cells in vitro and 
in vivo via the inhibition of proliferation and the enhancement of apoptosis.  
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4.2 Immunomodulatory effects of APN on NK cells 
4.2.1 AdipoRs expression on human NK cells 
First the distribution of AdipoRs was determined using flow cytometry on human CD56
+
 
peripheral blood NK cells. Remarkably, the majority of CD56
dim
 NK cells expressed both 
AdipoRs while only a minor fraction of CD56
bright




Figure 27: AdipoRs expression on human CD56
+
 NK cells. (A) Extra- (e.c.) and intracellular (i.c.) staining of 
AdipoR1 and AdipoR2 on CD56
+
 NK cells visualized by flow cytometry. One representative dot 
plot is shown. GAR indicates negative control and numbers represent the frequencies of positive 
cells. (B) Representative histograms of extracellular staining of AdipoR1 (upper panel) and 




 NK cells. Filled grey area represents negative 





cells. Data shown are mean±SEM. (AdipoR1 n=8; AdipoR2 n=4). Published in [113].  
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NK cells. (Fig. 27C) but a small fraction of both NK cell subsets 
remained negative for the extracellular as well as for the intracellular expression of AdipoRs 
(Fig. 27A).  
 
4.2.2 AdipoRs expression on murine NK cells 




 NK cells 
exhibited a similar expression pattern as it was illustrated for human (see Fig.8) and murine 
(see Fig.13) T cells. AdipoR1 and AdipoR2 expression was mainly limited to the cytoplasm 
of the analyzed cells. As shown in Figure 28A AdipoRs were expressed in the cytoplasm of 
nearly all Nkp46
+
 NK cells of WT mice while AdipoR1 surface expression was detected on 
14.5%±1 (mean±SEM) of murine NK cells of WT mice and mean 10.2%±1.3 (mean±SEM) 
of NK cells of APN-KO mice. Mean 15.5%±1.6 (mean±SEM) of NK cells of WT mice and 
mean 12.9%±3 (mean±SEM) of NK cells of APN-KO mice expressed the AdipoR2 
extracellularly (Fig. 28A and B).  
 
 
Figure 28: AdipoRs expression on murine splenic Nkp46
+
 NK cells. (A) Representative dot plots of AdipoRs 
expression on WT mice. Numbers indicate percentage of positive cells. GAR represents negative 
control. (B) Average of extracellular (e.c.) and intracellular (i.c.) AdipoRs expression on Nkp46
+
 
NK cells of WT and APN-KO mice. (C) Surface AdipoR1 expression on NK cells of WT and 
APNKO mice. Data are mean±SEM (n=5; *p<0.05). Partially published in [113].  
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Whereas the absence of APN had no influence on the intracellular expression levels of 
AdipoRs and the extracellular expression of AdipoR2 (Fig. 28B), AdipoR1 expression was 
significantly diminished in APN-KO mice as compared to WT mice (Fig. 28C).  
Murine NK cells are subdivided by the expression of CD11b and CD27 into four subsets 
characterizing their maturation status as described in section 1.4. Given that extracellular 
receptor expression could depend on developmental status of Nkp46
+
 NK cells, we used flow 
cytometry to analyze AdipoR1 distribution on the four subsets of murine NK cells in WT and 




 of WT 
as well as of APN-KO mice revealed significant higher AdipoR1 surface expression as 
compared to the more mature subpopulations.  
 
 
Figure 29: Surface AdipoR1 distribution on murine NK cell subsets of WT and APN-KO mice. (A) 
Surface AdipoR1 expression during developmental stages of murine Nkp46
+
NK cells of WT and 
APN-KO mice. (B) Comparison of extracellular AdipoR1 expression during particular maturation 
stages of murine NK cells of WT and APN-KO mice. Data are mean±SEM (n=5; *p<0.05).  
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During progression of murine NK cell maturation surface AdipoR1 expression significantly 
dropped down in both mice strains (Fig. 29A). Comparing AdipoR1 surface expression on 
NK cell subsets studies have showed that APN-KO mice exhibited a lower receptor 
expression during all maturation stages as compared to WT mice (Fig. 29B). Looking at the 




 63%±3 (mean±SEM) of NK cells of WT mice 
showed AdipoR1 surface expression compared to 42%±3 (mean±SEM)  of NK cells of APN-
KO mice.  
 
4.2.3 AdipoRs regulation on NK cells 
Whereas AdipoRs surface expression on T cells could be induced by activation, neither 
incubation with IL-2 nor with TLR-L was able to upregulate AdipoRs extracellularly on 
human CD56
bright 
NK cells in vitro (data not shown).  
In contrast, CVB3 infection of WT and APN-KO mice resulted in an upregulated surface 
expression of both AdipoRs on murine NKp46
+
 cells of WT and APN-KO mice (Fig.30). 
Similar results were also obtained for murine CD3e
+
 T cells (see Fig. 20).  
 
 
Figure 30: Regulation of surface AdipoRs expression on murine Nkp46
+
 NK cells. Surface AdipoRs 
expression in uninfected and CVB3 infected murine NK cells was analyzed by flow cytometry (n=5 
uninfected; n=4 infected; *p<0.05) Data are mean±SEM. Published in [113].  
 
4.2.4 Functional effects of APN on NK cells 
4.2.4.1 Human NK cells 




 NK cells we analyzed TLR-
L induced IFNγ secretion using intracellular cytokine staining. Freshly isolated PBMCs were  
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primed with IL-12, preincubated with APN and stimulated with LPS and R848 for 24h to 




 NK cells within PBMC cultures were determined 
for frequencies of IFNγ secretion.  
 
 
Figure 31: Functional effects of APN on TLR-L induced IFNγ secretion of human NK cells. (A) 
Frequencies of LPS and R848 induced IFNγ secretion of human NK cells within PBMCs (n=6; 
*p<0.05; ** p<0.01). (B) Frequencies of TLR-L induced IFNγ secretion of sorted human NK cells. 
Black bars indicated cultures raised in the absence of APN, grey bars represents cultures raised in 
the presence of APN (n=5; ns- not significant) Data were obtained by flow cytometry and are 
mean±SEM. Published in [113] 
 
Independent of APN, LPS and R848 significantly increased the IFNγ expression of NK cell 
(Fig. 31A). However, APN incubation resulted not only in a decreased TLR-L induced IFNγ 
response but also affected the spontaneous IFNγ production in human CD56+ NK cells.  
To find out if the inhibitory effect of APN on IFNγ secretion is directly, this assay was 
performed also with sorted human NK cells (Fig. 31B). Generally, IFNγ production of sorted 
NK cells was lower (Fig.31B) as compared to IFNγ secretion of NK cells cultured with 
PBMCs (Fig. 31A). APN preincubation did not diminish spontaneous or LPS induced IFNγ 
secretion of sorted CD56
+
 NK cells. R848 stimulated IFNγ production was lower, but this 
difference was not significant (Fig. 31B).  
To further determine the influence of APN on human NK cells the effects of APN on NK cell 
degranulation and cytotoxicity were studied and analyzed by flow cytometry. Degranulation 
of human CD56
+
 NK cells was analyzed by degranulation assay using mAb for the 
degranulation marker CD107a (Fig. 32A). IL-2 known as inducer of degranulation and 
cytotoxicity was used as a positive control. Human PBMCs were stimulated with APN, IL-2  
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or simultaneously with APN and IL-2 for 20h and incubated with K562 target cells in an 
effector to target ratio of 1:1 and 1:2.  
 
 
Figure 32: APN influence on human NK cell degranulation and cytotoxicity. (A) Frequencies of 
CD107a
+
 human NK cells treated with APN, IL-2 or simultaneously with APN and IL-2 and 
incubated without (black bars) and with K562 target cells at indicated ratios (n=3; ns-not 
significant). (B) Frequencies of K562 target cells killed by sorted human NK cells. NK cells 
were cultured with APN, IL-2 or simultaneously with APN and IL-2 and incubated at effector 
to target ratios of 1:1 (black bars) and 1:4 (grey bars) (n=5; ns-not significant). Control 
indicates non treated cultures. Data are mean±SEM. Published in [113].  
 
As shown in Figure 32A IL-2 induced CD56
+
 NK cell degranulation whereas APN had no 
impact on frequencies of CD107a
+
 NK cells as compared to non-treated controls. The co-
incubation with APN had no influence on IL-2 induced degranulation. Degranulation was 
dependent on effector to target ratio in all cases. Cytotoxicity was determined by the 
cytometric analysis of fluorescence labeled K562 target cells killed by sorted NK cells (Fig. 
32B). Again, APN had no effect on frequencies of killed target cells while IL-2 enhanced 
cytotoxicity as compared to non-treated and APN treated NK cell cultures. Induction was 
dependent on effector to target ratio. APN had no influence on neither basal nor IL-2 induced 
cytotoxicity of sorted human NK cells.  
Taken together, APN had no effect on spontaneous or IL-2 induced degranulation and 
cytotoxicity of human CD56
+
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4.2.4.2 Murine NK cells 
To study the functional effects of APN in vivo we compared NK cells of uninfected and 
CVB3 infected APN-KO and WT mice. We studied NK cell subsets and receptor 
composition, cytotoxicity and cytokine release. The determination of murine NK cells within 







 cells in spleens of APN-KO mice (Fig. 33A and B). 
 
 







 splenic NK cells of uninfected and three day infected WT and APN-KO mice. 




 NK cells 
in uninfected and infected WT and APN-KO mice (n=16 uninfected; n=5 three days after infection; 
n=12 seven days after infection; **p<0.01; *** p<0.001). (C) Absolute NK cell numbers per spleen 
calculated by flow cytometry of uninfected and infected WT and APN-KO mice (n=11 uninfected; 
n=5 infected; *p<0.05; ns-not significant). Published in [113].  
 
Increased percentages of NK cells were observed in APN-KO mice independent of infection. 
CVB3 infection resulted in diminished frequencies of splenic NK cells. Still three and seven 
days after infection NK cells of APN-KO mice remained higher as compared to frequencies 
of WT mice. Analysis of absolute splenic NK cell numbers also revealed higher cell counts in 
uninfected APN-KO mice as compared to WT mice (Fig. 33C). Upon CVB3 infection we 
could not observe higher NK cell numbers in spleens of APN-KO mice. To further analyze 
the effects of APN deficiency on murine NK cell composition we comparatively determined  
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NK cells subsets characterizing maturation status by CD11b and CD27 expression in spleens 
of uninfected and CVB3 infected WT and APN-KO animals (Fig. 34). In uninfected as well 





represented the major cell fraction within splenic Nkp46
+
 NK cells as measured by flow 




subset representing the most potent effector 
NK cells was decreased in uninfected APN-KO mice (Fig. 34A) whereas APN-KO animals 
showed elevated frequencies of these effector NK cells upon CVB3 infection as compared to 




 murine NK 
cell subset did not differ between uninfected and infected WT and APN-KO animals but were 
increased upon CVB3 infection in spleens of both mouse strains.  
 
 
Figure 34: Murine NK cell subsets of uninfected and infected WT and APN-KO mice based on CD11b 
and CD27 expression. (A) Frequencies of splenic NKp46
+
 NK cell subset in uninfected WT and 
APN-KO mice (n=5). (B) Frequencies of splenic NKp46
+
 NK cell subset in seven day CVB3 
infected WT and APN-KO animals (n=14). Data are mean±SEM (ns-not significant; *p<0.05; 
**p<0.01; ***p<0.001). Published in [113].  
 
Next the degranulation of uninfected and infected WT and APN-KO animals was studied by 
CD107a expression and measured by flow cytometry. Splenocytes were removed, counted 
and used for CD107a degranulation assay. CD107a expression was dependent on effector to 
target ratio (Fig. 35). As shown in Figure 35 NK cell degranulation was strongly increased 
upon CVB3 infection as compared to uninfected animals. Seven days after infection CD107a 
expression declined to similar levels as shown for NK cells of uninfected mice. In line with 
the decreased frequencies of effector NK cells in APN-KO mice (Fig. 34A) degranulation was 
diminished in uninfected APN-KO mice as compared to WT mice (Fig. 35 left).  
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Figure 35: Degranulation of murine NK cells of uninfected and infected WT and APN-KO animals. 
Frequencies of degranulating Np46
+
 NK cells within splenocytes of uninfected (left), three days 
infected (middle; 3d p.I.) and seven days infected (right; 7d p.I.) WT and APN-KO mice. CD107a 
secretion was analyzed in the absence (0) and in the presence of YAC-1 target cells in an effector to 
target ratio (splenocytes to YAC-1 cells) 50:1 and 100:1. Data are mean±SEM (n=5; ns-not 
significant; *p<0.05). Published in [113].  
 
Interestingly, degranulation of APN-KO mice was significant higher compared to WT mice 





effector NK cells at day seven (Fig. 34B).  
To further determine the mechanism underlying the impaired ability to degranulate of NK 
cells of APN-KO animals we studied the expression of NK cell activating receptors NKG2D 
and CD94 characterizing a subset with a higher proliferative and cytotoxic ability. Consistent 
with the degranulation data of uninfected APN-KO mice NKG2D expression was diminished 
in splenic and peripheral NK cells of uninfected APN deficient animals compared to WT mice 
(Fig. 36A and B). Upon CVB3 infection NKG2D was strongly downregulated on splenic and 
peripheral NK cells of WT and APN-KO mice at day three and seven (Fig. 36A-C), but was 
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Figure 36: NKG2D expression on NK cells of uninfected and infected WT and APN-KO animals. Mean 
fluorescence intensity (MFI) of NKG2D in uninfected and CVB3 infected WT and APN-KO splenic 
(A) (uninfected n=5; infected n=7) and peripheral (B) NK cells (uninfected n=10; infected n=9; ns-
not significant; **p<0.01). Data are mean±SEM. (C) Representative histogram of MFI NKG2D on 
splenic NK cells. Black line represents NK cells of uninfected and gray line of CVB3 infected 









 NK cells. Similar to NKG2D expression in WT and APN-KO mice (Fig. 36) analysis 
of CD94 by flow cytometry revealed lower frequencies of CD94
high
 NK cells in uninfected as 
well as in CVB3 infected APN-KO mice. In contrast, CD94 was not modulated upon CVB3 
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 subsets of murine NK cells in uninfected and infected WT and APN-KO 








 NK cells analyzed by flow 
cytometry. Infected animals were sacrificed at day seven (n=5, uninfected and n=14 infected; 
*p<0.05; **p<0.01). Data are mean±SEM. Published in [113].  
 
NK cell functionality is also defined by the ability of cytokine release. IFNγ expression of 
splenocytes of infected WT and APN-KO mice were determined by flow cytometry (Fig. 38). 
As demonstrated in Figure 38 CVB3 infection resulted in increased levels of NK cell secreted 
IFNγ. In line with degranulation and phenotype data infected APN-KO mice showed elevated 
frequencies of IFNγ producing NK cells.  
 
 
Figure 38: IFNγ production by NK cells of uninfected and infected WT and APN-KO mice. Frequencies of 
IFNγ producing murine CD3- Nkp46+ NK cells assayed in uninfected and seven day infected WT 
and APN-KO mice (n=6 WT; n=5 APN-KO; **p<0.01). Published in [113].  
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5 DISCUSSION 
Several previous in vitro and animal studies have already highlighted the importance of APN 
as an immunomodulator inhibiting the function of monocytes, macrophages and epithelial 
cells. Little has been known concerning its influence on T and NK cell function so far. This 
work investigated the effects of Adiponectin on T and NK cells in vitro and in adiponectin 
deficient mice exposed to CVB3 infection.  
 
5.1 APN and T cells 
T cells belonging to the adaptive immune system are the key players of anti-viral immunity. 
They are triggered when pathogens invade cells, are involved in the regulation of the adaptive 
immune response and are responsible for the specific elimination of pathogens.  
In a first report Pang and Narendran showed the expression of both APN receptors on a small 
population of T cells [25]. To extend these findings we analyzed AdipoRs expression on T 
cells using qRT-PCR, flow cytometry and immunofluorescence. In accordance, both receptors 
were expressed only on a small fraction of T cells. Investigations of receptor expression in 
CD3
+
 T cells and CD3 depleted PBMCs by qRT-PCR demonstrating high amounts of 
AdipoRs mRNA in CD3
+
 T cells prompted us to examine a potential intracellular depot of 





 T cells stored AdipoRs within the cytoplasm. Further, 
immunofluorescence staining of AdipoR1 and AdipoR2 demonstrated an internal storage in 
clathrin coated vesicles. Moreover, AdipoRs were co-expressed with TIRC7 and CTLA-4 in 
CD3
+
 T cells. Cytoplasmatic storage and clathrin dependent intracellular trafficking has been 
illustrated not only for TIRC7 and CTLA-4 [94, 114] but also for co-stimulatory proteins, 
including EGF-R and IFNγ [115, 116]. Regulation, induction and control of surface 
exposition of intracellular stored molecules require activating signals for membrane transport. 
Like described for TIRC7 and CTLA-4 [117] AdipoRs were exposed upon antigen activation 
on the surface of activated CD137
+
 T cells. Surface exposure occurred simultaneously with 
CTLA-4 surface expression within 72 hours and was detected up to nine days after antigen 
stimulation, an effect not observed on CD137
-
 T cells. Interestingly, analysis of influenza 
specific T cells characterized by tetramer and IFNγ staining and SEB activated T cells 
revealed an activation dependent upregulation of AdipoRs. AdipoRs surface expression was  
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not only induced upon TCR specific stimulation but also by polyclonal T cell activation.  
To test the functional consequence of AdipoRs upregulation on activated T cells we 
investigated the influence of APN on antigen activated CD137
+
 T cell. In vitro APN 
incubation resulted in a diminished generation of antigen activated T cells following antigen 
stimulation and assessment by CD137 and cytokine staining. While the expansion of antigen 
activated CD137
+
 and cytokine producing CD8
+
 T cells was reduced in antigen activated 
cultures the presence of APN had no effect on CD137
-





, T cells by exerting an anti-proliferating and apoptosis-promoting effect 
thereby leading to a diminished generation of antigen activated T cells. Engagement of 
upregulated CD137 on T cells is known to mediate co-stimulatory and anti-apoptotic 
functions, promoting T cell proliferation and T cell survival [91] by NFκB activation [118]. 
The upregulation of AdipoRs on CD137
+
 T cells enabling APN action on these cells provides 
receptors to negatively influence T cell expansion and to retract immune responses. Anti-
proliferating effects of APN were also described in endothelial cells [44], cancer cells [53, 54] 
myeloid [55] and myelomonocytic progenitor cells [79] where APN was found to 
downregulate anti-apoptotic gene transcription including the bcl-2 gene after 48h. Otherwise 
pro-apoptotic genes like p53, bak and bax were not affected [55]. The pro-apoptotic action on 
CD137
+
 T cells is in line with previous data demonstrating increased cell death caused by 
APN in hepatocellular carcinoma cells [48], gastric cancer cells [49] and endometrial 
carcinoma cells [50]. Further, APN exerted a direct inhibitory effect on antigen induced T cell 
cytokine production diminishing IFNγ and TNFα secretion in PBMCs cultures in vitro. A 
direct inhibitory APN effect has also been described for LPS induced TNFα [55], IL-6 [67] 
and IFNγ [68] secretion in macrophages constitutively expressing AdipoRs. APN diminished 
cytokine secretion was caused by a downregulation of mRNA transcription in consequence of 
suppressed NFκB translocation [67]. Given that the maximum of AdipoRs upregulation could 
be detected 72h after antigen stimulation on T cells the decreased cytokine production is 
suggest to be provoked or at least amplified by an APN dependent reduction of cytokine 
secretion of cells in the PBMC culture, mostly monocytes. Many effector functions of T cells 
are modulated by cells of the innate immune system [90] displaying abundant surface 
AdipoRs expression. To explore the influence of other PBMCs population on the reduced T 
cell cytokine secretion it would be necessary to perform these experiments in isolated CD3
+
 T 
cells. Further, the measurement of AdipoRs upregulation in isolated and antigen stimulated  
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 T cells and the blockade of AdipoRs by mAb would provide evidence of direct 
inhibitory function of APN on T cell cytokine secretion.  
Consistent with the human data analysis of murine AdipoRs expression revealed a minor 
fraction of CD3e
+
 T cells expressing surface AdipoR1 and AdipoR2. Expression was 
predominantly restricted to the cytoplasm of the analyzed cells. Moreover, like activated 
human T cells murine splenic T cells upregulated both receptors upon CVB3 infection. In 
contrast to studies by Bauche et al. where APN deficiency was shown to result in higher 
AdipoR2 expression levels compared to WT mice in adipose tissue [119] there was no 
difference in the AdipoRs expression pattern of resting and virus activated T cells of WT and 
APN-KO mice suggesting no influence of APN on the AdipoRs expression and regulation in 
murine T cells. Diet induced obesity was shown to upregulate murine AdipoR1 and AdipoR2 
in the liver and AdipoR1 in muscle [120] whereas acute exercise increased murine AdipoR1 
mRNA levels in liver and muscle [121]. To date there exist no further data about the 
expression and regulation of AdipoRs in murine T cells. The obtained murine data provide 
evidence of a similar AdipoRs regulation mechanism in T cells like we have shown for 
human T cells. In both cases antigen activation was followed by an upregulation of surface 
AdipoRs on T cells whereas resting T cells store both receptors intracellular. 
Similarly to the in vitro data describing APN as a negative T cell regulator, APN-KO mice 
revealed significantly higher frequencies of antigen activated CD137
+
 T cells upon CVB3 
infection. In the murine system the engagement of CD137 as a second signal for T cells is 
required for the T cell IL-2 production in response to antigen activation, enhances IFNγ 
production and promotes T cell expansion and survival [92]. Higher frequencies of CD137
+
 T 
cells in infected APN-KO mice result in an increased activation status of the immune system. 
In line with these findings several studies in APN-KO mice demonstrated beneficial effects of 
APN under inflammatory conditions. APN-KO mice are shown to be more susceptible to 
colitis [83] liver fibrosis [81] and sepsis provoked by increased cytokine levels [84]. Further, 





 T cells as well as increased TNFα and IFNγ levels [88]. APN 
administration in these disease models attenuated disease severity [80, 81]. The mechanism 
underlying the immunosuppressive effect of APN on T cells in vivo is most likely both 
directly and indirectly through innate immune cells. The generation of conditional knock-out 
of AdipoRs in PBMCs subsets except T cells would shed light on the direct effects of APN on 
T cells in vivo. As this is difficult to perform, a conditional knockout of AdipoRs on T cells  
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would provide an evidence of the indirect effects of APN.  
Our findings may also provide an explanation for the observation that obesity is associated 
with diminished APN production but elevated numbers of T cells, increased T cell activation 
and IFNγ expression in adipose tissue [122] leading to a chronic inflammatory response. The 
state of low-grade inflammation includes an increased expression of pro-inflammatory 
cytokines among others, TNFα and IL-6 which in turn suppress APN transcription. [18, 22]. 
Low levels of systemic APN concentrations perpetuate without attenuating mediators of 
inflammation and the activated immune status but rather promote inflammation, generating a 
self-sustained inflammatory loop.  
Although APN was shown to exert immunosuppressive function in animal models elevated 
APN serum levels found in chronic autoimmune diseases such as rheumatoid arthritis and 
inflammatory bowel disease [121] lead to the postulation of a dual effect of APN. APN has 
been shown to activate inflammatory processes including IL-6 and matrixmetalloproteinase-1 
(MMP-1) upregulation via the p38 MAP kinase pathway [123]. On the contrary APN has 
exhibited potential anti-inflammatory effects in a mouse model of rheumatoid arthritis. The 
delivery of adiponectin resulted in significantly reduced disease severity and decreased 
mRNA levels of pro-inflammatory cytokines [124, 125]. Increased adiponectin levels were 
also found in individuals suffering from inflammatory bowel disease exerting pro-
inflammatory effects by inducing cytokine production [126]. However, in experimental 
models of colonic inflammation, adiponectin-deficient mice have been reported to be either 
protected or more susceptible [83, 127]. Based on our data an alternate hypothesis is that APN 
is upregulated in autoimmune diseases through yet unknown factors in response to 
inflammation and acts as negative regulator to directly or indirectly modulate pathologically 
activated T cell response. Further, circulating and local adiponectin is composed of four 
isoforms hence it might be the ratio between them, rather than their respective concentrations, 
which determines the final action of this adipokine [23]. Whereas the HMW isoform is 
considered to exert pro-inflammatory actions, the LMW isoform is responsible for the anti-
inflammatory effects of adiponectin [22]. Thus, another explanation for increased APN levels 
acting in a pro-inflammatory way is the upregulation of a distinct adiponectin isoform in 
chronic autoimmune diseases shifting the ratio of the present oligomers and provoking pro-
inflammatory effects. In contrast to disorders typically associated with excess adiposity, like 
type 2 diabetes and cardiovascular diseases, APN levels are elevated in disorders unrelated to  
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increased adipose tissue suggesting the presence of a different adiponectin regulation 
mechanism and/or its isoforms with opposite functions. 
In summary this study describes a novel function of APN as a cytokine negatively regulating 
T cell expansion and function attenuating an overwhelming T cell response. In contrast to 
other immunoregulatory receptor-ligand interactions being restricted to the interplay between 
immune cells, APN is abundant in human plasma and may exhibit an important role in 
systemic T cell regulation as well as provides an additional link between the immune system 
and metabolism.  
 
5.2 APN and NK cells 
Natural killer cells are innate effector lymphocytes involved in the first defense against 
infected or malignant cells. They act directly through mediating cellular cytotoxicity and 
secretion of cytokines essential for the clearance of infectious pathogens [98] and indirectly 
through regulation of the immune system [128].  
Besides the expression of AdipoRs on T cells Pang and Narendran also demonstrated the 
presence of both receptors on a subset of human NK cells suggesting an immunomodulatory 
role of APN for NK cells [25]. In agreement, we found surface AdipoRs expression on the 
majority of CD56
dim 
subset of human blood NK cells, whereas the majority of CD56
bright
 NK 
cells were negative on the surface expressing both receptors intracellularly. However, a small 
fraction of both NK cell subsets lacked both surface and intracellular expression. Like shown 
for T cells displaying an intracellular storage of AdipoRs and surface upregulation upon TCR 
stimulation we supposed and confirmed a similar cytoplasmatic depot in CD56
bright
 NK cells. 
We could not further upregulate AdipoRs surface expression neither by IL-2 nor TLR-L 
stimulation on CD56
dim
 NK cells. As CD56
bright 
NK cells are proposed as precursors of the 
CD56
dim
 subset [129, 130] they exhibit a different surface receptor phenotype resulting in 
distinct functions. CD56
bright
 NK cells have been shown to have low to absent expression of 
killer cell immunoglobulin-like receptors (KIRs), but high levels of CD94-NKG2A inhibitory 
receptors, whereas the opposite is true for CD56
dim
 NK cells [105]. Further, both subsets show 
a different repertoire of chemokine receptors and adhesion molecules [131]. Maturation 
dependent NK cell receptor expression was also shown in murine NK cells [107]. AdipoRs 
expression may therefore be developmentally regulated during maturation being absent on the 
surface of CD56
bright
 and transducing their signals only to CD56
dim
 NK cells.  
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In line with the anti-inflammatory effects of APN observed on DCs, epithelial cells, 
monocytes and macrophages [36, 55, 68, 70] APN was observed to inhibit TLR-L induced 
IFNγ production in human NK cells in PBMCs cultures. A suppression of TLR response and 
reduction of IFNγ was also described in human macrophages [68, 69]. However, the 
inhibitory effect of APN on IFNγ production of NK cells was indirect, as it was not seen in 
TLR-L stimulated sorted human NK cells thus mediated indirectly by other cells and/or 
factors. NK cells express constitutively receptors for monocyte- and macrophage-derived 
cytokines (monokines) hence their responsiveness can be modulated by monocytes and 
macrophages [105]. APN diminished monokine secretion by accessory cells could result in 
decreased NK cell IFNγ production. Since APN was shown to downregulate C-C chemokine 
receptors (CCR) type 2 and CCR5 in monocytes [132] it also could impair the levels of NK 
cell monokine receptors reducing binding options and stimulatory effect of monokines on 
IFNγ secretion. Consistently, APN was shown to inhibit TLR family induced NFκB signaling 
in macrophages [69] thus resulting in the suppression of NFκB target genes including 
chemokines and chemokine receptors. Additionally, the absence of AdipoRs on the potent 
cytokine producing CD56
bright
 NK cells [105, 106] corroborated the indirect action of APN on 
human NK cells. Interestingly, degranulation and cytotoxicity assessed by CD107a secretion 
and in vitro killing assay were not influenced by APN. Differential mechanism were 
postulated for the regulation of NK cell IFNγ production and cytotoxicity [133, 134] Our 
results are in accordance with the study of O’Shea et al. in which APN did not inhibit human 
NK cell cytotoxicity but partially restored the unfavorable effects of cigarette smoke [109]. 
On the contrary APN previously was shown to act as a negative regulator of NK cell 
cytotoxicity and IFNγ production in murine NK cells [71]. Differences between both studies 
may be attributed to unphysiological high concentration of APN used in vitro by Kim et al. 
The inhibitory effect was observed at 20µg/ml APN while lower amounts had no effects on 
neither NK cell cytotoxicity nor on IFNγ secretion in their study.  
Interestingly, we identified a major difference between human and murine NK cells surface 
AdipoRs expression, which we observed only on a minor subset of resting murine NK cells.  
Most murine NK cells stored AdipoRs intracellular and upregulated surface AdipoRs 
expression upon infection indicating an immunomodulatory role of APN mostly in activated 
murine NK cells, and resembling the upregulation of AdipoRs on human and murine T cells 
upon antigen activation. Surface AdipoR1 distribution was decreased in APN-KO mice  
 
  Discussion 
 
  68 
 
compared to WT mice during all maturation stages. Moreover, AdipoR1 was regulated 





 NK cell subset in both mice strains. As shown for human NK cells also murine NK 
cells display maturation dependent receptor expression [107]. Interestingly, on the contrary to 




 NK cell subset 
showed the highest receptor expression suggesting the most prominent influence of APN not 
only on activated NK cells but on the first developmental stages of murine NK cells.  
To further study the potential immunoinhibitory role of APN on NK cell function we 
compared CVB3 infected WT and APN-KO mice. Unexpectedly, we detected however, 
increased NK cells with a lower frequency of effector NK cells and diminished cytotoxic 
function in uninfected APN deficient mice suggesting a role of APN in NK cell maturation. In 
this regard a modulatory effect of APN on monocyte precursors and B lymphopoesis has been 




 NK cell 
subset representing the most potent effector NK cell subset [107, 108] we observed 
diminished NK cell degranulation in uninfected APN-KO mice. In addition, expression of 
NKG2D, an activating receptor required for NKG2D-dependent cytolytic activation [135-
137] was decreased in APN-KO mice. Further the CD94
high
 NK cell subset possessing a 
higher proliferative and cytotoxic potential [138] was diminished in APN-KO mice. Upon 




 NK cell subset as well as cytotoxic 
function and IFNγ production were, however, restored, suggesting that APN plays a role in 
NK cell maturation and distribution but is not crucial for NK cell function. The general 
downregulation of NKG2D expression on NK cells we observed upon CVB3 infection is in 
accordance with the study by Muntasell et al. [139] who similarly observed downregulation 
of NKG2D in response to CMV infection while the percent of degranulating NK cells 
triggered by NKp46 increased upon infection. 
The effect of APN on activated NK cells cannot be adequately addressed in the APN-KO 
model since APN-KO mice had less functional NK cells per se. Based on the enhanced NK 
cell function observed upon infection in APN-KO mice one may, however, speculate that this 
is due to the lack of an inhibitory signal provided by APN.  
In summary, our work describes APN as an indirect negative NK cell regulator in humans. 
This finding is in line with a number of previous studies having underscored the importance 
of APN as an immunoregulator for macrophages and as shown here for T cells in vitro as well 
as in various animal models. Moreover we show that compared to humans murine NK cells  
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differentially express AdipoRs and in human and murine NK cells were regulated 
developmentally. Further, APN-KO mice have lower frequencies of effector NK cells whose 
functionality is somehow restored upon infection. Thus in addition to its anti-inflammatory 
effects APN influences also number and differentiation status of NK cells. 
Our data implicate APN as anti-inflammatory molecule with immunosuppressive properties 
and therapeutic potential. Of special interest in this regard is the observation that APN inhibits 
anti-viral memory and effector T cell and NK responses in vitro and in our animal model of 
autoimmune myocarditis (EAM), a model of human inflammatory cardiomyopathy (DCMi) 
[140]. In line with this APN exerted anti-inflammatory effects in patients with DCMi. 
Elevated APN concentrations were associated with better hemodynamic outcome in patients 
with DCMi. Also the effect of APN on regulatory T cell function which similar to 
conventional T cells store AdipoRs mostly intracellular (own unpublished results) may play 
an important role in immunoregulation.  
Taken together these data suggest that APN up-regulation may be a promising therapeutic 
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